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ABSTRACT 




Metastatic melanoma historically carries a grim prognosis, with a median survival 
of 9 months and a long-term survival rate of 10%. Melanoma is highly immunogenic, and 
the development of immunotherapies has dramatically changed the landscape of 
metastatic melanoma treatment. To study the immune mechanisms engaged by these 
therapies, the Bosenberg lab developed YUMMER, an immunogenic mouse melanoma 
line that forms tumors when injected into mice. This and other immunogenic murine 
cancer models were used to demonstrate that B cell depletion does not impair the anti-
PD-1-induced anti-tumor immune response in mice. In addition, supplementing immune 
checkpoint inhibition with therapies targeting myeloid cells increases the efficacy of 
immune checkpoint inhibitors and can convert resistant tumors into sensitive tumors. 
Last, a novel model was developed that allows for comparison of failed and successful 
anti-tumor immune responses, and we propose how it may be employed to study the 
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Chapter One: Background and Literature Review 
 
 
Melanoma is a malignant neoplasm of melanocytes that accounts for the majority 
of skin cancer deaths despite comprising less than 5% of all cutaneous malignancies (1, 
2). Its incidence has increased faster than that of any other cancer over the past half-
century, and the annual costs of treatment in the United States alone have risen rapidly 
(1, 3-6). Although the majority of primary melanomas are cured with local excision, 
metastatic melanoma historically carries a grim prognosis, with a median survival of 9 
months and a long-term survival rate of 10% (7, 8). Given the urgent need to develop 
treatment strategies for metastatic melanoma, there has been extensive research into 
both the genetic alterations that cause melanocytes to become malignant as well as the 
interactions between melanoma cells and the immune system. The knowledge gained 
from this research has led to the development of animal models of melanoma, which 
have, in turn, informed novel treatment strategies. This chapter will first review the 
genetic changes thought to contribute to the malignant features of melanoma. It will then 
examine the current therapeutic landscape for metastatic melanoma with a particular 
emphasis on immunotherapy. Finally, it will explain the development and characteristics 
of the Yale University Mouse Melanoma (YUMM) model and its irradiated counterpart, 
the Yale University Mouse Melanoma Exposed to Radiation (YUMMER) model. 
 
A. The Genetics of Melanoma  
1) Cutaneous Melanoma 
Cutaneous melanomas have historically been classified into superficial 
spreading, nodular, lentigo maligna, desmoplastic, mucosal, or acral subtypes based 
upon anatomic site and histologic morphology (9). The most common subtype is 
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superficial spreading melanoma, which is thought to originate in the epidermis before 
entering a vertical growth phase and invading into the dermis. In contrast, nodular 
melanoma is thought to progress to a vertical growth phase more rapidly. Lentigo 
maligna melanoma presents as a slow-growing macule or patch in sun-exposed skin 
and typically affects elderly patients. Desmoplastic melanoma is also associated with 
sun exposure, is locally infiltrative, and has a lower rate of metastasis to draining lymph 
nodes. Mucosal melanoma affects mucous membranes while acral melanoma affects 
palmoplantar and subungual skin. Mucosal and acral melanomas share the 
characteristic that they typically have less sun exposure than other forms of cutaneous 
melanoma and are frequently classified together as acral lentiginous melanomas (ALM) 
(10, 11). ALM accounts for less than 3% of all primary melanomas (12, 13) but is the 
most common subtype in people of African and Asian heritage and has a similar 
incidence in all ethnicities and skin types (14). 
The clinical utility of this classification scheme has been called into question, 
however, both because a significant proportion of melanomas fail to fit neatly into a class 
and because histologic subtype is not an independent prognostic factor (15). Recent 
efforts examining the genetics of melanoma on a large scale have allowed for synthesis 
of genetic data with the historic classifications, allowing for a greater understanding of 
the biologic underpinnings of melanoma types and the role of sun exposure. In this 
section, we will first review the role of ultraviolet radiation in melanomagenesis, then the 
known genetic drivers that underlie cutaneous melanomas arising on intermittently sun-
exposed (non-CSD) skin, and follow with a discussion of melanomas associated with 






Exposure to ultraviolet radiation has long been considered an important 
environmental risk factor for cutaneous melanoma. Genetic studies have supported this 
notion, revealing that cutaneous melanomas harbor a very high somatic mutation burden 
relative to other tumor types (17). Approximately 45% of mutations in melanoma are 
cytosine-to-thymine or tandem CC-to-TT transitions, while approximately 10% are 
guanine-to-thymine transversions (18). This is consistent with exposure to UV-B 
radiation, which is known to cause crosslinking of adjacent pyrimidine bases (CC, CT, 
TC, or TT). When recognized by DNA polymerases, two adenine bases are often 
inserted opposite to the dimerized pyrimidines, and during the subsequent replication 
cycle, the alteration is incorrectly repaired resulting in C-to-T or CC-to-TT transitions 
(19). Less commonly, G-to-T transversions have been reported (20). Both the rates of 
single nucleotide variants and mutations among melanomas are highest on CSD skin 
and lowest in acral and mucosal sites (21).   
 
Non-CSD melanoma 
MAP Kinase pathway  
Greater than 80% of melanomas on non-CSD skin have been found to harbor 
mutations that constitutively activate the MAP Kinase/ERK signaling pathway, which 
regulates cell proliferation and survival (11). Data from The Cancer Genome Atlas 
(TCGA) cohort revealed that non-CSD melanomas can be classified into BRAF, RAS, 
NF1, and triple-wild type subtypes based upon the most prevalent mutations affecting 
this pathway (21). BRAF is the most commonly mutated gene and is altered in 
approximately 50% of non-CSD melanomas. BRAF encodes a serine-threonine kinase 
that phosphorylates MEK (MAP2K) when bound to active RAS-GTP (22, 23). Up to 90% 
of BRAF mutations affect exon 15 and result in V600E substitutions that cause 
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constitutive activation of BRAF (22); less common substitutions include V600K, V600R, 
and K601E (21). Approximately 25% of melanomas contain mutations in NRAS, which 
encodes a small G protein that binds to and activates BRAF when in the GTP-bound 
state (21). Most NRAS mutations are found either within exon 1 leading to substitution of 
glycine at position 12 or 13 or within exon 2 leading to substitution of glutamine at 
position 61; in both cases, mutation prevents hydrolysis of GTP leading to constitutive 
activation of both NRAS and its downstream effectors (11). In addition to NRAS, rare 
mutations in HRAS (G13D, G13S, and Q61K) and KRAS (G12D, G12R, and Q61R) 
were identified in tumors from the TCGA cohort (21). Of note, BRAF and RAS mutations 
are seldom, if ever, detected in the same tumors (22). Other perturbations in the MAP 
Kinase pathway include loss-of-function mutations in the genes for RAS GTPase-
activating proteins (GAPs) NF1 and RASA2 that are found in approximately 15% and 5% 
of non-CSD melanomas, respectively (18, 24), and gain of function mutations in MEK1 
(MAP2K1) and MEK2 (MAP2K2) that have been identified in 8% of non-CSD 
melanomas (25). Interestingly, NF1 mutations were found to be anti-correlated with 
BRAF mutations but not with NRAS mutations in tumors from the TCGA cohort (21).  
Despite the prevalence of BRAF and NRAS mutations in non-CSD melanomas, 
these mutations are insufficient to drive malignancy in isolation. It is well known that 
benign acquired nevi and benign congenital nevi predominantly contain BRAF and 
NRAS mutations, respectively (26, 27). BRAF mutations have also been shown to 
induce growth arrest in vitro (28). This suggests that constitutive activation of BRAF 
triggers checkpoint mechanisms designed to restrict malignant growth, a phenomenon 
known as oncogene-induced senescence (OIS) (28). To overcome OIS, additional 
mutations or epigenetic changes, often affecting the PI3 Kinase pathway and/or 
CDKN2A, are necessary (29).  
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PI3 Kinase pathway 
Up to 50% of non-CSD melanomas exhibit mutations affecting the PI3 Kinase 
pathway and its effectors (11). Inactivation of PTEN, a phosphatase that 
dephosphorylates PIP3 and thereby inhibits the anti-apoptotic function of Akt, was 
identified in 10% of tumors in the TCGA cohort, while other studies have reported PTEN 
mutations, deletions, or epigenetic silencing in up to 30% of non-CSD melanomas (11, 
30, 31). In addition to PTEN inactivation, gain-of-function mutations or amplifications 
affecting the catalytic subunits of either PI3 Kinase (4%) or Akt (up to 30%) may be 
present (32, 33). 4-9% of tumors contain mutations in the gene encoding RAC1, a small 
G protein in the Rho family that induces lamellipodia formation and contributes to cell 
motility downstream of PI3 Kinase and other pathways in vitro (11). The most commonly 
identified mutation, a P29S substitution, is caused by a cytosine-to-thymine transition 
consistent with UV-B exposure. This mutation results in increased GDP/GTP nucleotide 
exchange that favors the active form of RAC1 and is thought to enhance cell migration 
and proliferation (24, 34). Gain-of-function mutations in the gene encoding PREX2, a 
guanine nucleotide exchange factor (GEF) for RAC1, were also found in 26% of non-
CSD melanomas in the TCGA cohort, although its role as a driver mutation remains 
unclear (35). Finally, greater than 15% of tumors in the TCGA cohort contain mutations 
in components of the mTOR signaling pathway that operates downstream of Akt 
including MTOR, TSC1, TSC2, RICTOR, and RPTOR (21).  
 
CDKN2A 
Although known for being the most commonly altered gene in familial melanoma, 
somatic loss-of-function mutations in CDKN2A were found in 15% of tumors in the 
TCGA cohort, and losses or epigenetic downregulation have been reported in up to 70% 
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of sporadic melanomas (16, 36). This gene encodes both p16/INK4a, a G1-CDK 
inhibitor, and p14/ARF, a protein that blocks MDM2-mediated degradation of p53 (11).  
 
TERT 
Mutations in the promoter region of telomerase reverse transcriptase (TERT), a 
component of the telomerase holoenzyme, are found in up to 70% of melanomas (37-
40). Consistent with UV signature, cytosine-to-thymine transitions at one of four 
positions upstream of the transcriptional start site have been shown to produce new 
binding motifs for the ETS transcription factor GA-binding protein (GABP) that lead to 
increased expression of TERT and therefore increased telomerase activity, which may 
enable cells to overcome senescence (41).  
 
MITF 
The MITF locus on chromosome 3p is amplified in 10% of non-CSD melanomas 
(36, 42). MITF, or microphthalmia-associated transcription factor, is a basic helix-loop-
helix transcription factor that is responsible for melanocyte differentiation and function 
(42). It is known to control expression of several cell cycle regulators and pro-
proliferative proteins including CDK2, TBX2, CDKN2A, p21, Bcl2, and c-Met as well as 
HIF-1α, which is believed to promote tumor survival and metastasis (43). Additionally, 
transcription of MITF is known to be upregulated by canonical WNT signaling through β-
catenin, and gain-of-function mutations in CTNNB1 (β-catenin) are found in 5-7% of non-
CSD melanomas (44).  
 
Other genes 
Analysis of the TCGA cohort has led to the implication of several other genes in 
melanoma tumorigenesis. 34% of tumors contain somatic mutations in GRIN2A, the 
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gene encoding the ionotropic glutamate receptor NMDAR2A, that prevent NMDA-R 
complex formation, increase anchorage-independent growth, and increase cell migration 
in vitro (45). Similarly, 23% of tumors contain somatic mutations in GRM3, the gene 
encoding metabotropic glutamate receptor 3, that have been shown to disrupt 
melanosome trafficking via dysregulation of cAMP signaling (46, 47). Approximately 16% 
of non-CSD melanomas were found to harbor loss-of-function mutations in TP53, which 
encodes a protein that restricts cell cycle progression in response to DNA damage (18, 
21, 37). In addition, upregulation of MDM2 and MDM4, E3 ubiquitin ligases that signal 
p53 degradation, has also been observed in a subset of tumors (48). 7% of tumors 
contain mutations in PPP6C, the gene encoding a phosphatase known to restrict G1-to-
S phase transition (18, 49). 7% contain mutations in ARID2, a gene encoding a 
component of the PBAF chromatin-remodeling complex and known tumor suppressor 
(18). 6% of tumors contain mutations in DDX3X, a gene encoding a DEAD-box RNA 
helicase involved in translation initiation and stress granule assembly, resulting in 
globally reduced translation that may provide a survival advantage to tumor cells (50). 
Less common mutations affect citric acid cycle enzyme IDH1 (5.7%), tumor suppressor 
RB1 (4.3%), 40 S ribosomal protein RPS27 (2.6%), and mitochondrial ribosomal protein 
MRPS31 (1.3%) (21, 51). 
 
Chromosomal aberrations 
Prior to the advent of deep sequencing technology, cytogenetic approaches were 
used to study the genetics of melanoma. Commonly reported alterations found in non-
CSD cutaneous melanomas include losses on chromosomes 1p, 4, 5, 6q, 8p, 9p, 10q, 
11q, 12q, 14, 15, 16, 21, and 22 and gains on chromosomes 1q, 6p, 7, 8q, 18, and 20q; 
of note, AKT3 is located on chromosome 1q, BRAF is located on chromosome 7q, and 
CDKN2A is located on chromosome 9p (11, 52-54). 
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Acral, mucosal, and CSD melanoma  
Chromosomal aberrations  
Several studies have shown that acral and mucosal melanomas harbor 
significantly increased chromosomal aberration when compared to both non-CSD and 
CSD melanomas (16, 55, 56). Up to 89% of acral melanomas and 85% of mucosal 
melanomas have been shown to contain gene amplifications, in contrast to infrequent 
amplifications found in both non-CSD and CSD melanomas (13, 16). The most 
commonly identified structural variations include gains in 4q, 5p, 6p, 11q, 12q, and 22q 
and losses in 6q, 9p, and 10 (16, 54, 56, 57), many of which upregulate the activity of 
the G1-S cyclin-dependent kinase. In particular, 10% of acral or mucosal melanomas 
have gain in the CDK4 gene on chromosome 12q, up to 45% demonstrate gain in the 
CCND1 gene on chromosome 11q, and approximately 60% demonstrate loss in the 
CDKN2A gene on chromosome 9p (13, 55, 58).  
 
KIT and PDGFRA 
Unlike non-CSD melanomas, amplifications of chromosome 4q containing the 
gene for the receptor tyrosine kinase KIT are found in approximately 30% of mucosal 
melanomas and 25% of acral melanomas while gain-of-function mutations are found in 
approximately 20% of mucosal melanomas and 10% of acral melanomas (13, 59). 28% 
of CSD melanomas also harbor KIT mutations or amplifications (59). Among ALM and 
CSD melanomas, KIT alterations are rarely if ever found in tumors that also contain 
BRAF or NRAS mutations (59). Most KIT mutations occur in exon 11, 13, 17, or 18, and 
the most common mutations are the substitutions L576P on exon 11, K642E on exon 13, 
and V559A on exon 11 (37, 38, 60), resulting in constitutive kinase activity and 
stimulation of both the MAP Kinase and PI3 Kinase pathways (61). Of note, this 
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spectrum of mutations overlaps with that of both sporadic and familial gastrointestinal 
stromal tumors (44, 62).  
Also located on chromosome 4q, the gene for receptor tyrosine kinase PDGFRA 
is commonly amplified in ALM (21, 55). Gain-of-function mutations in the gene have also 
been reported in up to 6.8% of acral melanomas and 3.6% of mucosal melanomas (13, 
63). These mutations cause ligand-independent activation of the receptor leading to 
dysregulated melanocyte proliferation, differentiation, and migration (63, 64). Notably, 
PDGF is thought to play a role in melanocyte epithelial-to-mesenchymal transition (EMT) 
that precedes metastasis (65). In contrast to ALM, neither CSD nor non-CSD 
melanomas commonly contain aberrations in PDGFRA (63).   
 
BRAF and NRAS 
Unlike non-CSD melanomas, ALM and CSD melanomas less commonly contain 
mutations in BRAF. Although reports vary, BRAF mutations are found in approximately 
3-11% of mucosal melanomas, 21-23% of acral melanomas, and 6-11% of CSD 
melanomas (16, 44, 55). In contrast to BRAF mutations, NRAS mutations occur at a 
similar rate of approximately 10-25% among acral, mucosal, CSD melanomas, and non-
CSD melanomas (66). 
 
Other genes 
Other genes that have been implicated in acral or mucosal melanoma include 
MITF, PREX2, ARID1A, PTEN, TP53, AURKA, and APC (18, 24, 35, 57, 67, 68). In 
contrast to non-CSD melanomas, only 6-11% of ALM contain TERT promoter mutations 
(55, 69). Up to 25% of acral melanomas, however, have been found to contain copy 
number gains in the TERT gene (68). Mutations in DDX3X, RASA2, PPP6C, RAC1, or 
RB1 are rarely reported in ALM (55). 
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2) Ocular melanoma 
Ocular melanoma is the most common primary malignancy of the eye among 
adults (70), although it comprises only 5% of all melanoma (71). It arises in the uvea in 
95% of cases and in the conjunctiva in the remaining 5% (70). Information regarding the 
genetic alterations in conjunctival melanoma is scarce, but the available data suggest 
that these tumors have more in common with cutaneous melanomas than uveal 
melanomas. Indeed, BRAF, NRAS, and TERT mutations are commonly found in both 
cutaneous and conjunctival melanomas but not in uveal melanomas (11, 72). Of note, 
unlike cutaneous melanoma, uveal melanoma is not considered to be related to UV 
exposure (73). Below, we will review the known genetic drivers of uveal melanoma.  
 
GNAQ/GNA11 
The most commonly mutated genes in uveal melanomas include GNAQ and its 
paralog, GNA11, affecting 45% and 32% of primary uveal melanomas, respectively (74, 
75). Both genes encode the α subunit of a heterotrimeric Gq protein that functions to 
activate the protein kinase C, MAP Kinase, and YAP1 pathways via a phospholipase C-
dependent mechanism (76). 97% of the reported mutations consist of Q209L or Q209P 
substitutions in exon 5 while the remaining 3% consist of R183C substitution in exon 4; 
all of these mutations impair the intrinsic GTP-ase activity, producing an increase in 
downstream signaling (74, 75). Recently, activating mutations have been identified both 
upstream and downstream of GNAQ/GNA11 signaling. In a subset of uveal melanomas, 
a L129Q substitution in the gene encoding CYSLTR2, a leukotriene-sensing G-protein-
coupled receptor (GPCR) that acts as a GEF for GNAQ/GNA11, has been shown to 
favor the active conformation and increase GNAQ/GNA11 activity (77, 78). PLCB3 and 
PLCB4, both genes that encode phospholipase C enzymes activated by GNAQ/GNA11, 
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have recently been found to harbor K898N and D630Y substitutions, respectively, 
although the role of these genes in oncogenesis is unclear (77, 79).  
 
BAP1 and other genes 
Up to 40% of uveal melanomas contain inactivating (usually truncating) 
mutations affecting BAP1 (BRCA1 associated protein-1) (80, 81), a protein that has 
been shown to play a role in DNA repair (82), melanocyte differentiation (83), and 
epigenetic regulation of the RB1 gene (11, 71, 84). Recurrent mutations have also been 
identified in EIF1AX, a gene encoding a component of the 43S preinitiation complex that 
aids in recruitment of the 40S ribosomal subunit to mRNA, and SF3B1, a gene encoding 
a component of the U2 small ribonucleoprotein (snRNP) involved in RNA splicing (81, 
85). Of note, mutations in EIF1AX and SF3B1 occur almost mutually exclusive to each 
other and to mutations in BAP1 (85).  
Uveal melanomas are commonly classified into one of two prognostic groups 
based on their gene expression profiles (86). Melanomas in the first group, which harbor 
mutations in either EIF1AX or SF3B1, are associated with low risk of metastasis (85) 
while melanomas in the second group, which harbor mutations in BAP1, are associated 
with high metastatic risk (87). Approximately 80% of metastatic uveal melanomas 
contain truncating mutations in BAP1 (80) and target the liver in up to 90% of cases (88). 
Interestingly, BAP1 mutations usually arise early in tumor evolution and are followed by 
a period of neutral evolution before tumors become clinically evident, suggesting that the 
metastatic potential of uveal melanoma is determined early in its course (87).  
 
Chromosomal aberrations 
Commonly reported chromosomal aberrations in uveal melanoma include 
monosomy of chromosome 3, gain in 1q, 6p, and 8q, and loss in 1p, 6q, 8p, and 16q 
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(11, 54, 70, 71). Monosomy 3, found in up to 50% of cases, is associated with worse 
prognosis and losses in BAP1 (located on chromosome 3p), while 8q gain is also 
associated with worse prognosis (89). 
 
3) Familial melanoma 
Between 5 and 10% of cutaneous melanomas are thought to arise in the context 
of a family history of melanoma (11, 90). Approximately 40% of these tumors are 
associated with loss-of-function mutations in CDKN2A, resulting in loss of p16/INK4A, a 
key negative regulator of cell cycle progression (90, 91). Additionally, germline gain-of-
function mutations in CDK4 including R24C and R24H have been reported; these 
mutations prevent the interaction between CDK4 and p16/INK4 resulting in increased 
CDK4 activity and cellular proliferation (11, 92). Patients with familial retinoblastoma due 
to germline alteration of the RB1 cell cycle regulator are also at increased risk for 
cutaneous melanoma (93). Other candidate genes that may explain up to 2% of familial 
cutaneous melanoma include BAP1 (94, 95) along with the genes encoding telomere-
associated proteins POT1, ACD, TERF2IP, and TERT (96).  
In addition to these highly penetrant yet rare mutations, more common single 
nucleotide polymorphisms (SNPs) in MITF and MC1R have been associated with 
intermediate risk of cutaneous melanoma (11). A recently discovered germline mutation 
in MITF causing a E318K substitution has been found to impair post-translational 
SUMOylation of MITF leading to increased transcription of its target genes including 
CDK2, Bcl2, c-Met, and HIF-1α (43, 97-99). MC1R encodes the melanocyte stimulating 
hormone receptor that controls MITF expression and the pigmentation process. Variants 
in this gene have been associated with synthesis of the less photoprotective pigment, 
pheomelanin, and the resulting red hair color phenotype (100). These variants also 
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inhibit the interaction between MC1R and PTEN, allowing for increased activation of the 
PI3 Kinase pathway (101).  
1-2% of uveal melanomas are thought to be hereditary (11), although less is 
known about the genetics of familial uveal melanoma than familial cutaneous melanoma. 
Germline BAP1 mutations in uveal melanomas have been reported, and recent studies 
have suggested that inherited BAP1 mutations predispose patients to cutaneous 
melanoma, uveal melanoma, mesothelioma, renal cell carcinoma, and several other 
tumors (71). In contrast to familial cutaneous melanoma, CDKN2A mutations and MC1R 
variants do not seem to be associated with uveal melanoma (102). 
 
Conclusion 
Analysis of genomic data from large melanoma tumor cohorts has led to the 
discovery of several genetic changes thought to drive melanomagenesis. In this section, 
we reviewed these changes as well as the signaling pathways that they affect. 
Importantly, this understanding of melanoma genetics has informed the development of 
several targeted therapies now used to treat patients with metastatic disease. The 
following section will discuss these and other therapeutic options in the treatment of 










B. Therapeutic Options for Metastatic Melanoma 
  As mentioned in the introduction, the majority of primary cutaneous melanomas 
can be cured surgically, with margins of excision determined by the tumors’ depths of 
invasion observed on biopsy: 5 mm margins are recommended for in situ melanomas, 1 
cm margins are recommended for melanomas that are up to 1 mm in thickness, 1-2 cm 
margins are recommended for melanomas that are 1-2 mm thick, and 2 cm margins are 
recommended for melanomas that are thicker than 2 mm (103). In cases of metastatic 
melanoma, however, surgery is rarely sufficient to achieve cure. Instead, other treatment 
modalities including chemotherapy, targeted therapy, and immunotherapy are often used 
in addition to or in lieu of surgical excision. In this section, we will review the current 
therapeutic options for metastatic melanoma, placing particular emphasis on 
immunotherapies, as these medications have shown the most promise in treating this 
devastating disease.    
 
1) Chemotherapy 
Prior to the development of therapies targeting aberrant signaling cascades and 
immune cells, treatment of metastatic melanoma often involved chemotherapy using the 
alkylating agent dacarbazine or its prodrug, temozolomide (TMZ). While at one point the 
standard of care for metastatic melanoma, dacarbazine therapy results in a complete 
response in less than 5% of patients, a median progression-free survival of 2.2 months, 
and a 5-year survival in only 2-6% of patients (104); TMZ has been shown to be even 
less effective than dacarbazine (105). In both cases, the lack of efficacy is thought to be 
due to melanoma cells’ inherent resistance to apoptosis (106). Although no longer the 
standard of care for metastatic disease, dacarbazine and TMZ continue to be employed 
in the treatment of refractory and relapsed melanomas (107).  
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2) Targeted Therapy 
 The advancements in melanoma genetics reviewed in chapter 1A identified 
several potential therapeutic targets that have since led to the development of novel 
mutation-specific therapies. For this reason, genetic sequencing of melanoma tissue is 
now an important component of a melanoma patient’s initial evaluation. Small molecule 
inhibitors of BRAF including vemurafenib and dabrafenib, for example, have been 
approved to treat metastatic melanomas that harbor gain-of-function mutations in BRAF 
(108, 109). In clinical trials, vemurafenib was shown to improve clinical response rates, 
progression-free-survival, and overall survival in patients with BRAF-mutant melanomas, 
and up to 90% of tumors treated with vemurafenib demonstrated partial regression 
(109). As previously discussed, mutations in NRAS and BRAF do not co-occur, and 
therefore, BRAF inhibition is not a valid strategy for treating NRAS-mutant melanomas 
(22). 
Despite these promising findings, however, initially sensitive tumors quickly 
develop resistance to BRAF inhibitors through multiple mechanisms including the 
acquisition of activating mutations in genes encoding other MAP Kinase pathway 
molecules such as MEK and NRAS as well as activation of the PI3 Kinase pathway via 
loss of PTEN activity (110). In order to address this, inhibitors of MEK have been 
developed, including trametinib and cobimetinib (111). When compared to 
chemotherapy, trametinib monotherapy was reported to improve clinical response rates, 
progression-free-survival, and overall survival in patients with BRAF-mutant melanomas 
who had not received BRAF inhibitor therapy (112). Even better outcomes have been 
seen with BRAF inhibitor/MEK inhibitor combination therapies including 
trametinib/dabrafenib and cobimetinib/vemurafenib, which have been approved for 
metastatic, BRAF-mutant melanomas (113). In patients with untreated and unresectable 
BRAF-mutant metastatic melanoma, cobimetinib/vemurafenib has been shown to 
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produce a complete or partial response in 69.9% of patients and a median progression-
free survival of 12.3 months, in contrast to the 50% response rate and 7.2-month median 
progression-free survival in similar patients treated with vemurafenib alone (114). Since 
the development of even more effective immunotherapies, however, these combination 
regimens have been used in patients who either fail or cannot tolerate immune therapy. 
 In contrast to non-CSD melanomas, acral lentiginous and CSD melanomas often 
harbor mutations or amplifications in KIT. For patients with these aberrations who have 
failed or cannot tolerate immune therapy, small molecule tyrosine kinase inhibitors with 
activity against KIT, including imatinib, sunitinib, dasatinib, and nilotinib, can be 
employed (115). Clinical trials of imatinib therapy in patients with KIT-mutant melanomas 
have shown an approximately 30% response rate with a median progression-free 
survival of 3-4 months; patients with KIT amplifications are less responsive to targeted 
therapy than are patients with KIT mutations (116-118).  
 In addition to medications directed against components of the MAP Kinase 
pathway and KIT, several other targeted therapies are being evaluated for use in 
metastatic melanoma. These include antibodies against vascular endothelial growth 
factor (VEGF) such as bevacizumab, inhibitors of PI3 Kinase such as PI-103, mTOR 
inhibitors such as rapamycin and everolimus, and CDK4/6 inhibitors including ribociclib; 
many of the ongoing clinical trials are assessing whether combining these therapies with 




Melanoma is known to be one of the most immunogenic tumor types, with 
immune-mediated spontaneous regression occurring in approximately 3% of melanomas 
(123). Further evidence of its propensity to spontaneously regress lies in the fact that 5% 
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of melanoma patients present with metastases that harbor mutations classically found in 
non-CSD melanomas but lack any sign of a primary tumor (124). The effector cell of this 
anti-tumor immune response is thought to be the tumor-infiltrating lymphocyte (TIL), a 
hypothesis supported by the observation that the density of TILs on histologic 
examination of biopsied melanomas positively correlates with patient survival (125, 126). 
TILs have been found to recognize melanocyte differentiation antigens including gp100, 
tyrosinase, and MART-1/Melan-A (127-129); they have also been shown to recognize 
the gene-products of aberrantly-expressed melanoma-associated genes (MAGE) as well 
as neoepitopes formed from the expression of somatically-mutated genes (130). In light 
of its strong association with UV exposure, it is perhaps unsurprising that cutaneous 
melanoma has the greatest somatic mutation burden of any known cancer (18, 24). 
Given the immune system’s ability to recognize and kill melanoma cells, it follows that 
the development of immunotherapies has dramatically changed the landscape of 
metastatic melanoma treatment. 
 
Interferon α-2b 
The first immune therapy was interferon (IFN) α-2b, a type I interferon that 
activates natural killer (NK) cells, T cells, and dendritic cells in addition to suppressing 
viral replication (131). IFN α-2b has been shown to both inhibit VEGF secretion by 
melanoma cells and upregulate major histocompatibility complex (MHC) class I 
expression on the surface of melanoma cells, allowing for increased recognition by 
cytotoxic T cells and thus, increased apoptosis (132). IFN α-2b has been approved as 
adjuvant therapy for patients with either high risk of disease progression following 
excision or lymph node metastasis, and it has been shown to both reduce recurrence 
risk and improve overall survival in patients whose tumors are responsive (133, 134). 
The strongest predictors that a patient would benefit from adjuvant IFN α-2b therapy 
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include ulceration of the primary tumor (135), high tumoral pSTAT1/pSTAT3 ratio (136), 
high serum levels of pro-inflammatory cytokines including IL1β, IL-6, and TNF-α (137), 
and dense infiltration of metastatic lesions by CD4+ lymphocytes (138).  
A pegylated variant of IFN α-2b has also been approved for melanomas that 
have metastasized to the lymph nodes (139). Peginterferon α-2b is formed through the 
covalent attachment of a polyethylene glycol (PEG) moiety to IFN α-2b, resulting in a 
compound with an increased half-life (140). Although shown to increase relapse-free 
survival following tumor resection, it does not increase overall survival when compared 
to observation alone (141). It is also associated with higher rates of immune related 
adverse events (irAEs) than its non-pegylated counterpart (142). 
In addition to monotherapy, combination therapies with IFN α-2b have been 
evaluated for efficacy against metastatic melanoma. IFN α-2b has been combined with 
IL-2, dacarbazine, cisplatin, and vinblastine to create “biochemotherapy,” which shows 
higher response rates and increased progression-free survival when compared to 
dacarbazine monotherapy; this regimen, however, is associated with significant toxicity 
and does not increase overall survival (143). Studies evaluating the effects of combining 
IFN α-2b with immune checkpoint inhibitors as well as BRAF inhibitors are currently 
underway (131, 144).   
 
Interleukin-2 
 Interleukin-2 (IL-2), a cytokine that stimulates the proliferation of T lymphocytes 
(145), was approved for the treatment of metastatic melanoma after early trials 
demonstrated objective partial responses in a subset of patients (146). A recent meta-
analysis of over 3000 patients with metastatic melanoma demonstrated that high-dose 
IL-2 therapy results in complete responses in 4% of patients and partial responses in 
12.5% of patients, with an overall response rate of 19.7% (147). Despite the promising 
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anti-tumor effects of IL-2, however, it also causes increased capillary permeability and 
fluid extravasation that manifest as a host of severe clinical toxicities including diarrhea, 
shock, and even death (148). These severe toxicities have become less common in 
recent years, as dosing regimens have been adjusted to reflect increased understanding 
of the side effect profile; while the rate of treatment-related deaths was initially between 
2% and 4%, it is now less than 1% (148). Although newer immune therapies have been 
able to achieve similar response rates with less severe toxicities, IL-2 remains an option 
for relatively healthy patients with metastatic melanoma and is still included in clinical 
trials as part of combination regimens (122).  
 Like effector T cells, regulatory T cells (Treg) also express receptors for IL-2 
(149). Because these cells are thought to suppress T cell-mediated killing and are often 
found in the tumor microenvironments (TME) of patients with poor outcomes, a fusion 
protein made from IL-2 and diphtheria toxin has been investigated as a method of 
selectively eliminating circulating Tregs (150). Although one study reported partial 
responses in 16.7% of patients treated with this fusion protein (151), another study 
reported that regulatory T cells were not cleared from circulation and no objective 
response was observed (152).  
 
Immune checkpoint inhibition 
T cell activation requires the presence of two stimulatory signals. The first of 
these signals occurs when MHC-bound antigens on the surfaces of antigen presenting 
cells (APCs) bind to T cell receptors (TCR); the second signal involves recognition of the 
co-stimulatory molecules B7-1 and B7-2 (CD80 and CD86) by CD28 molecules 
expressed on the membranes of T cells (153). When both signals are present, the 
signaling cascade from the TCR is maximally activated, leading to production of pro-
proliferative IL-2 and its receptor, IL-2R, as well as expression of chemokine receptors 
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that enable the activated T cells to migrate towards target tissues (153). Without this 
second signal, however, T cells remain in an anergic state (153). 
In addition to CD28, T cells express the CD28-like proteins, cytotoxic T-
lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1), that bind co-
stimulatory molecules with higher affinity than does CD28 (154). In contrast to CD28, 
however, these molecules function to inhibit the TCR signal. When bound to B7-1 or B7-
2 on APCs, CTLA-4 recruits the phosphatases SHP2 and PP2A, which dephosphorylate 
both the T cell receptor complex and Akt, resulting in a dampening of the TCR signal 
(155). The ligands for PD-1 include PD-L1 (B7-H1) and PD-L2 (B7-CD), both of which 
are also expressed by APCs (156). Similar to CTLA-4, active PD-1 recruits 
phosphatases SHP1 and SHP2, resulting in dephosphorylation of the T cell receptor 
complex and dampening of TCR signaling (157). Interestingly, melanoma cells have 
been shown to express PD-L1, which likely serves to locally inhibit the anti-tumor 
immune response (158). 
Whether a T cell becomes activated in the presence of an MHC-bound antigen 
depends on the ratio of co-stimulatory molecules binding the lower-affinity CD28 to those 
binding the higher-affinity CTLA-4 and PD-1. In the absence of local inflammation, APCs 
express co-stimulatory molecules at low levels (159). In this state, they are more likely to 
bind to higher-affinity CTLA-4 and PD-1, thus ensuring that T cells remain anergic and 
do not attack non-inflamed, self tissues. In the presence of pathogen- and damage-
associated molecular patterns (PAMPs and DAMPs), however, pattern recognition 
receptors such as toll-like receptors (TLRs) are stimulated, leading to upregulation of co-
stimulatory molecules (159). In this state, co-stimulatory molecules are more likely to 
bind to lower-affinity CD28, allowing for TCR signaling to proceed. This is a critical 
“immune checkpoint” that functions to ensure that T cells become active only in the 
presence of a pathogen or other source of tissue damage (159).  
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Due to their pivotal role in regulating whether T cells are able to respond to 
antigens, CTLA-4, PD-1, and PD-L1 are attractive targets for immunotherapy. The 
relatively new class of immunotherapies known as immune checkpoint inhibitors function 
to inhibit these molecules, thereby disinhibiting T cell activation (154). The first of these 
therapies, ipilimumab, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody 
directed against CTLA-4 that prevents it from binding B7-1/B7-2 (160). It was approved 
for treatment of metastatic melanoma in 2011 after clinical trials demonstrated a median 
overall survival of 10.1 months with ipilimumab monotherapy (161) and of 11.2 months 
when combined with dacarbazine (162). Responses are seen in up to 19% of patients, 
and median progression-free survival is 2.9 months, which is increased from that of 
chemotherapy. Furthermore, responses to ipilimumab are durable in a significant 
number of patients, with 4-year overall survival ranging from 13.8% to 49.5% (163). 
Apart from ipilimumab, another antibody targeting CTLA-4, tremelimumab, is currently 
being assessed in clinical trials, although it has yet to show improvement in overall 
survival (164).  
Nivolumab is a humanized IgG4 monoclonal antibody directed against PD-1 that 
inhibits co-stimulatory molecules from binding to PD-1 (165). Approved for treatment of 
metastatic melanoma in 2014, nivolumab therapy has a 40% response rate and median 
progression-free survival of 6.9 months, longer than that of both ipilimumab therapy and 
chemotherapy (166). This increases to 11.5 months when nivolumab is combined with 
ipilimumab; such a combination is particularly beneficial to patients whose tumors do not 
express PD-L1 (166). Another anti-PD-1 antibody, pembrolizumab, was approved in 
2015, and has been shown to produce a 46-48% six-month progression-free survival 
rate, a 68-75% one-year overall survival rate, and a 32-34% response rate as compared 
to a 26.5% six-month progression-free survival rate, a 58.2% one-year overall survival 
rate, and a 19% response rate with ipilimumab therapy (167). In addition to antibodies 
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targeting PD-1, anti-PD-L1 therapies such as atezolizumab, avelumab, and darvalumab 
are currently being assessed for efficacy against metastatic melanoma (122). 
The effects of immune checkpoint inhibition are not limited to malignant tissues, 
however. Immune activation is often nonspecific, and autoimmune toxicities, or irAEs, 
commonly affect patients on these regimens (160, 168). High grade toxicities that 
require temporary or permanent cessation of immune checkpoint inhibitor therapy have 
been seen in approximately 27% of patients treated with ipilimumab monotherapy, the 
most common of which are dermatitis, enterocolitis, endocrinopathy, and hepatotoxicity 
(8). Similar toxicities are seen in 10-15% of patients treated with PD-1 or PD-L1 
inhibitors and in 55% of patients treated with a combination of ipilimumab and nivolumab 
(8). PD-1 inhibitors, in particular, have been associated with severe pneumonitis that has 
been fatal in rare cases (165). In addition, fulminant myocarditis, brittle diabetes, and 
severe neurologic disorders such as multiple sclerosis, Guillain-Barre Syndrome, and 
myasthenia gravis have all been described in patients receiving immune checkpoint 
inhibitor therapy (169). Interestingly, studies have shown that an anti-tumor immune 
response is more likely to occur in patients that develop irAEs (170). 
The treatment of an irAE depends upon its severity. Low-grade toxicities are 
typically managed with corticosteroids and symptom control while high-grade and life-
threatening toxicities require systemic corticosteroids and changes to the 
immunotherapy regimen (8). While most irAEs respond to corticosteroids, some are 
refractory and require additional immune suppression (8). With this in mind, it is 
important to understand the mechanisms by which different irAEs occur. Although most 
irAEs are considered to be off-target effects of T cell activation, B cell-mediated 
autoantibody secretion has been linked to some toxicities, including autoimmune 
hemolytic anemia and bullous lichenoid dermatitis (171). Chapter two will discuss an 
experiment in which we utilized our melanoma model to determine whether treating such 
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irAEs with therapies that deplete B cells would hinder the anti-tumor effects of anti-PD-1 
therapy. Such experiments will be important as the use of immune checkpoint inhibitors 
continues to expand.   
 
Adoptive cell therapy 
 Another approach to accessing the anti-tumor potential of T cells is called 
adoptive cell therapy. This process involves the in vitro expansion of TILs derived from a 
resected melanoma and the subsequent infusion of these cells back into the patient 
(172). The success of this approach hinges on a brief in vitro expansion phase and 
depletion of host lymphocytes prior to infusion. Such depletion is thought to reduce 
competition for pro-proliferative cytokines such as IL-7 and eliminate suppressive Tregs 
from the circulation (172). Clinical trials of adoptive cell therapy paired with harsh 
lymphocyte depletion regimens including cyclophosphamide, fludarabine, and total body 
irradiation reported objective response rates of up to 72% and durable complete 
responses in 10-20% of patients (173). Toxicities of the lymphodepletion regimen were 
common and severe, however, and more recent protocols have accepted somewhat 
lower objective response rates of 40-50% in order to avoid total body irradiation (174). 
 An alternative to traditional adoptive cell therapy involves infusing patients with 
genetically engineered T cells that express tumor-specific receptors called chimeric 
antigen receptors (CAR) (175). These receptors are formed by genetically fusing 
variable regions of tumor antigen-specific antibodies to a transmembrane domain that 
interacts with the T cell receptor complex (176). The resulting CAR genes are 
transferred into T cells using a retroviral or lentiviral vector, and the CAR-TCR is 
expressed, thus forming CAR-T cells. Although this approach has not yet been approved 




 Although immune checkpoint inhibitors are the current drugs of choice for 
patients with metastatic melanoma, research into melanoma immunology continues to 
expand, inspiring novel immunotherapies in the process. One example, a genetically 
modified herpes virus called talimogene laherparepvec (T-VEC), was approved in 2015 
for the treatment of unresectable and metastatic melanoma (177). This lytic virus is 
injected directly into melanoma tumors and replicates only in malignant cells, leading to 
rupture of tumor membranes and leakage of melanoma antigens into the surrounding 
tissue; APCs present these antigens and proceed to activate T cells (177). Early-phase 
clinical trials with T-VEC have shown a 28% objective response, and other trials are 
ongoing (178).  
Another novel therapy approach involves vaccinating patients with gp100, a 
glycoprotein expressed by melanoma cells and recognized by TILs (179). Although 
vaccination alone did not produce benefits in preclinical models, combination therapy 
with IL-2 improved progression-free-survival, median overall survival, and complete 
response rate when compared to IL-2 monotherapy (180). 
  
Conclusion 
 There has been an immense amount of progress in the field of metastatic 
melanoma treatment since the days when dacarbazine was the most promising option 
for patients. The fact that immune checkpoint inhibitors have produced durable, 
complete responses in a subset of patients and are now considered first-line therapy for 
metastatic melanoma underscores their profound impact on the treatment landscape. 
Despite these successes, however, both primary and acquired resistance limit many 
patients from realizing the benefits of immune checkpoint inhibitor therapy. For this 
reason, there is continued need for research into the precise mechanisms used by these 
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medications as well as the mechanisms by which they fail. Because addressing many of 
the questions that underlie these aims would be infeasible in humans, high-quality 
animal models that recapitulate the properties of human melanoma are necessary. The 
following section will detail the development and characteristics of such a model that 























C. The Yale University Mouse Melanoma Model  
 Much of what is currently known about melanoma was discovered using murine 
models. The most widely used model, B16, was derived from a melanoma that arose 
spontaneously in an inbred C57Bl/6J mouse. Developed by Harold E. Harding and R. D. 
Passey in 1930, it has since been employed to study both basic melanoma biology and 
anti-tumor immune responses. Despite its utility, however, four important limitations 
restrict its ability to generate translatable findings, particularly within the scope of 
melanoma immunology. First, in contrast to human melanomas, retroviral elements in 
the B16 genome have been shown to play an important role in tumorigenesis (181). 
Second, it is a unique line without obvious analogs, thereby making validation 
experiments difficult. Third, the driver mutations that contribute to tumor formation in the 
B16 model are unknown, and as a consequence, it is difficult to assess the effects of 
specific melanoma genotypes using the model. Fourth and perhaps most important, B16 
melanomas grow rapidly and express low levels of MHC Class I molecules, thereby 
restricting their immunogenicity (182). 
 With these limitations in mind, several groups have set out to develop 
genetically-engineered mouse models (GEMM) to better recapitulate human 
melanomas. The first such GEMM of melanoma was a BRAFV600E/PTEN-/- mouse model 
first described in 2009 (183). To generate this model, mice heterozygous for a Cre-
recombinase-dependent BRAFV600E allele and homozygous for a floxed PTEN allele 
were crossed with mice harboring melanocyte-restricted estrogen-receptor-linked Cre 
recombinase under the control of the Tyrosinase promoter; the resulting Tyr::CreER; 
BRAFCre-dependent V600E/+; PTENlox/lox offspring rapidly and reliably develop melanomas at 
the sites of topical 4-hydroxytamoxifen administration (183).  
Additional GEMMs have since been created using similar techniques, allowing 
for several of the common genetic signatures discussed in chapter 1A to be studied in 
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mouse melanoma models. A major drawback to these GEMMs, however, is the difficulty 
inherent to maintaining the mouse colonies required to produce offspring with the target 
genotypes (181). To address this, the Bosenberg lab set out to generate a library of 
GEMM-derived cell lines that would reliably grow tumors when grafted into 
immunocompetent C57Bl/6J mice. Meeth, et al. backcrossed several relevant alleles to 
C57Bl/6J mice and subsequently interbred the resulting mice to create inducible models 
of several melanoma genotypes. Melanomas were induced on these mice using 4-
hydroxytamoxifen, and cell lines were generated from resulting tumors using a standard 
protocol (Figure 1C.1). Collectively, these cell lines are known as the Yale University 
Mouse Melanoma (YUMM) lines (181) and represent the majority of documented 
melanoma genotypes including BRAF-mutant, NRAS-mutant, and BRAF/NRAS/NF-1 
wildtype (Figure 1C.2). As discussed in chapter 1A, gain-of-function mutations in BRAF 
are often accompanied by loss-of-function mutations in either PTEN or CDKN2A, 
allowing cells to overcome oncogene-induced senescence; this is reflected in the YUMM 
lines.  
 
Figure 1C.1: Flowchart depicting melanoma induction and YUMM line generation. 
Adapted from  “The YUMM lines: a series of congenic mouse melanoma cell lines with 















Figure 1C.2: Driver mutations in various YUMM lines. 
 
 Tumors grown from injected YUMM cells grew significantly faster than those 
induced on their corresponding GEMMs, reaching a volume of 1 cm3 within seven weeks 
(Figure 1C.3). Despite this difference in growth rate, YUMM tumors were histologically 
similar to their corresponding GEMM tumors, providing reassurance that genetic drift 
had not played a significant role during production of the cell lines. Additionally, BRAF-
mutant YUMM tumors were shown to exhibit a pattern of initial vemurafenib sensitivity 
followed by acquired resistance in vivo (Figure 1C.4), thereby mimicking the behavior of 
human melanomas (181). 
 Like B16 melanomas, however, YUMM melanomas are poorly immunogenic. 
When YUMM1.7 cells (a specific line with the YUMM1 genotype) were injected into both 
wildtype and RAG1-/- mice that are deficient in T and B cells due to loss of somatic 
recombination, tumors grew at a similar rate, suggesting that a functional adaptive 
Name Genotype 
YUMM1 BrafV600EPten-/- Cdkn2a-/- 
YUMM2 BrafV600EPten-/- Bcatsta/+ 
YUMM3 BrafV600ECdkn2a-/- 
YUMM4 Pten-/- Cdkn2a-/- 




YUMM9 NrasQ61R Cdkn2a-/- 
YUMM10 NrasQ61R p53-/- 
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immune system does not hinder YUMM cell growth (Figure 1C.5A). 
Immunohistochemical examination of YUMM tumors grown in immunocompetent mice 
revealed that approximately 40% of nucleated cells within tumors were CD45+ 
leukocytes, the majority of which were F4/80+ tumor-associated macrophages; less than 










Figure 1C.3: Growth rate of YUMM tumors. YUMM cells injected into C57Bl/6J mice 
form 1 cm3 tumors within 7 weeks. Adapted from  “The YUMM lines: a series of congenic 




Figure 1C.4: YUMM tumors treated with BRAF inhibitors. YUMM tumors are initially 
sensitive to BRAF inhibition (left) but develop resistance after prolonged exposure 
(right). PLX4720 is a BRAF inhibitor. Adapted from  “The YUMM lines: a series of 




Figure 1C.5: YUMM1.7 tumors are poorly immunogenic. A. YUMM1.7 tumors grow at 
a similar rate regardless of adaptive immune function. B. Lymphocytes comprise a 
minority of intratumoral leukocytes in YUMM tumors. Adapted from  “The YUMM lines: a 
series of congenic mouse melanoma cell lines with defined alterations” by Meeth, et al. 
(2016). PMC5331933. 
 
 The YUMM lines harbor the driver mutations, but not the significant “passenger” 
mutation burden, characteristic of human melanomas (17). As previously discussed, 
melanomas are among the most somatically mutated tumors, with an average mutation 
rate of 16.8 mutations per megabase per exome observed in tumors analyzed by TCGA 
(21). These mutations are largely consistent with ultraviolet signature and do not appear 
to influence the growth or mitotic behavior of cells (184). They are, however, thought to 
encode “neoantigenic” peptides that increase the immune recognition of melanoma cells 
through presentation on MHC Class I molecules. This is supported by the observation 
that high somatic mutation burden is positively correlated with responsiveness to 
immune checkpoint inhibitor therapy (185, 186). 
 In order to better recapitulate the immunogenicity of human melanomas, the 
Bosenberg lab next sought to increase the somatic mutation burden of YUMM cells 
(187). YUMM1.7 cells in culture were irradiated with three rounds of 1500J/m2 UV-B 
light, and a single irradiated cell was clonally expanded, giving rise to a new cell line 
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known as YUMM Exposed to Radiation-1.7, or YUMMER1.7 (Figure 1C.6). Whole 
exome sequencing of YUMMER1.7 cells demonstrated 1446 unique mutations not 
present in the parental YUMM1.7 line, 81.5% of which were C-to-T transitions consistent 
with UV-B exposure; these mutations were stable through multiple cell passages.  
 
Figure 1C.6: Development of the YUMMER1.7 line. To generate YUMMER1.7 cells, 
YUMM1.7 cells were irradiated with three rounds of UV-B, and a clone was derived from 
a single irradiated cell.  
 
 Injections of 100,000 YUMMER1.7 cells were administered to the flanks of 
immunocompetent and RAG-/- C57Bl/6J mice, and tumor volume measurements were 
obtained. In 80% of immunocompetent mice, a “spontaneous regression” phenotype was 
observed, in which tumors initially grew before regressing completely (Figure 1C.7). 
Even higher rates of spontaneous regression were seen when fewer than 100,000 cells 
were injected. In all RAG-/- mice, however, tumors grew at a rate similar to that observed 
with YUMM1.7 injection, thus demonstrating that spontaneous regression is mediated by 
lymphocytes. Further experiments showed that spontaneous regression is lost with 
antibody-mediated depletion of both CD4+ and CD8+ T lymphocytes, indicating that the 
phenotype is T cell-dependent (Figure 1C.8). Interestingly, there appears to be a 
threshold above which the immune system is unable to contain tumor growth, as 
injections of greater than 250,000 YUMMER1.7 cells produce tumors in both 
immunocompetent and immunodeficient mice (Figure 1C.9). 
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Figure 1C.7: Spontaneous regression with YUMMER1.7. YUMMER1.7 tumors 
regress following an initial growth phase in wildtype mice (left). Regression does not 
occur in immunodeficient mice (right). Adapted from “UV-induced somatic mutations 
elicit a functional T cell response in the YUMMER1.7 mouse melanoma model” by 









Figure 1C.8: Spontaneous regression is T cell-dependent. T cell depletion eliminates 
the spontaneous regression phenotype. Adapted from “UV-induced somatic mutations 
elicit a functional T cell response in the YUMMER1.7 mouse melanoma model” by 








Figure 1C.9: Tumor formation with YUMMER1.7. Spontaneous regression does not 
occur with injections of 250,000 of more cells. Adapted from “UV-induced somatic 
mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma 
model” by Wang, et al. (2017). PMC5820096. 
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A key property of the adaptive immune system is the development of memory 
cells that recognize and swiftly eliminate previously encountered antigens. Given that 
spontaneous regression of YUMMER1.7 tumors was determined to be T cell-dependent, 
it was hypothesized that YUMMER1.7 cells injected following a spontaneous regression 
would be promptly rejected. To test this, C57Bl/6J mice that had successfully rejected 
injections of 100,000 YUMMER1.7 cells were rechallenged with 500,000-cell injections 
to their opposite flanks. Tumor growth was not observed in any of these rechallenged 
mice, a result that starkly contrasts the robust tumor growth seen when naïve mice are 
injected with 500,000 YUMMER1.7 cells. This memory response was T cell-dependent, 
as it disappeared with antibody-mediated depletion of CD4+ and CD8+ T lymphocytes 
(187).  
To further investigate the immune infiltrate in YUMMER1.7 tumors, GFP-labeled 
YUMMER1.7 cells were injected into mice, and tumors were harvested at various time 
points. CD45+ and CD3+ infiltrates increased over time in regressing tumors formed 
from 100,000-cell injections while remaining relatively steady in escaping tumors formed 
from 500,000-cell injections (Figure 1C.10). Cleaved caspase-3, a marker of apoptosis, 
was also shown to increase as tumors regressed. Additionally, the ratio of Foxp3+ Tregs 
to total CD3+ T cells remained relatively low in regressing tumors while it increased in 
escaping tumors (Figure 1C.11). As a control, GFP-labeled YUMM1.7 cells were injected 
into mice, resulting in tumor formation in all cases. Compared to escaping YUMMER1.7 
tumors, YUMM1.7 tumors contained significantly less CD3+ infiltration, suggesting that 
the immune system recognizes but fails to contain escaping YUMMER1.7 tumors (187). 
The reason for this failure is of great interest to basic science researchers and 
clinicians alike, as clinically significant melanomas have, by definition, escaped immune 
control. One theory is that immunosuppressive elements in the tumor microenvironment 
including Tregs and myeloid-derived suppressor cells (MDSC) produce signals that deter 
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T cells from entering tumors and killing malignant cells. This is supported by the 
observation that Tregs comprise an increasing proportion of all TILs as YUMMER1.7 
tumors grow out (Figure 1C.11) (187). Another theory is that prolonged exposure to 
tumor antigens in the absence of strong co-stimulatory signals may induce T cells to 
adopt an exhausted phenotype, as has been observed in chronic viral infections (188). 
Chapter four will discuss several experiments intended to gauge whether this occurs. 
Finally, it is possible that the increased overall mitotic rate that characterizes higher 
inoculation numbers overwhelms the immune system’s capacity to recognize and kill 










Figure 1C.10: Immune infiltration in YUMMER1.7 tumors. YUMMER1.7 tumors 
formed from 100,000-cell injections (left) exhibit increasing CD45+, CD3+, and F4/80+ 
infiltrates as they regress. YUMMER1.7 tumors formed from 500,000-cell injections 
(right) exhibit relatively stable CD45+, CD3+, and F4/80+ infiltrates and eventually grow 
out. Adapted from “UV-induced somatic mutations elicit a functional T cell response in 






Figure 1C.11: Tregs in YUMMER1.7 tumors. YUMMER1.7 tumors formed from 
100,000-cell injections (left) exhibit a relatively stable ratio of Tregs to T cells. 
YUMMER1.7 tumors formed from 500,000-cell injections (right) exhibit an increasing 
ratio of Tregs to T cells as they grow out. Adapted from “UV-induced somatic mutations 
elicit a functional T cell response in the YUMMER1.7 mouse melanoma model” by 
Wang, et al. (2017). PMC5820096. 
 
 
Regardless of the specific mechanism or mechanisms by which large inocula of 
YUMMER1.7 cells escape immune control, the injection of 500,000 YUMMER1.7 cells 
provides an ideal model with which to study immune therapies. Wang, et al. showed that 
while 100% of isotype control-treated tumors progressed to an endpoint of 1 cm3 volume 
by day 32 post-injection, 80% of anti-CTLA-4-treated tumors, 40% of anti-PD-1-treated 
tumors, and 100% of dual anti-CTLA-4/anti-PD-1-treated tumors regressed completely 
and did not return during an observation period of 180 days (Figures 1C.12 and 1C.13). 
Tumor growth was significantly delayed in the few tumors that did progress on 
immunotherapy. These results were validated in repeat experiments, and checkpoint 
blockade was found to be most effective when started on post-injection day 7 and 
administered every other day for three weeks. In contrast to immunogenic YUMMER1.7 
tumors, YUMM1.7 tumors are insensitive to immune checkpoint blockade and reach 







Figure 1C.12: YUMMER1.7 tumors are sensitive to immune checkpoint inhibitors. 
Survival curves comparing mice bearing YUMMER1.7 tumors (left) or YUMM1.7 tumors 
(right) treated with either immune checkpoint inhibitors or isotype control. Adapted from 
“UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 
mouse melanoma model” by Wang, et al. (2017). PMC5820096. 
 
 
Figure 1C.13: YUMMER1.7 tumors are sensitive to immune checkpoint inhibitors. 
Spider plots comparing growth of YUMMER1.7 tumors treated with anti-CTLA-4 (top 
left), anti-PD-1 (top right) or both (bottom) to untreated tumors. Adapted from “UV-
induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse 





 The recent proliferation of genetic technologies has provided researchers with 
the ability to design melanoma GEMMs that harbor the clinically relevant driver 
mutations discussed in chapter 1A. Tumors derived from these GEMMs are more similar 
to human melanomas than are B16 melanomas, thereby increasing the likelihood that 
experimental results will translate to the clinic. The YUMM lines are a series of 
syngeneic melanoma cell lines derived from C57Bl/6J GEMMs that collectively represent 
the known genetic subsets of melanoma. When injected, these cells form tumors in 
C57Bl/6J mice that are initially sensitive to targeted therapy but develop resistance after 
a period of exposure. They are poorly immunogenic, however, and do not respond to 
immune checkpoint inhibitors. To increase their immunogenicity, YUMM1.7 cells were 
irradiated with ultraviolet light to increase their somatic mutation burden. The resulting 
YUMMER1.7 cells exhibit several important growth characteristics. First, tumors formed 
from small numbers of YUMMER1.7 cells (<100,000) spontaneously regress in a T cell-
dependent fashion. Second, tumors formed from large numbers of YUMMER1.7 cells 
(>250,000) uniformly grow out despite exhibiting T cell infiltration. Third, treatment with 
immune checkpoint inhibitors allows for complete and durable regression in a subset of 
these high-inoculum tumors. These properties of YUMMER1.7 cells make them an 
attractive model with which to study basic melanoma immunology as well as 
immunotherapy. 
With this in mind, the following three chapters will discuss experiments 
conducted in the Bosenberg lab using the YUMMER lines. Chapter two will explore the 
role of B lymphocytes in the anti-tumor immune response and the potential for B cell 
depletion as treatment for certain irAEs. Next, chapter three will discuss whether 
manipulation of myeloid cells in the tumor microenvironment can convert immune-
resistant tumors into immune-sensitive tumors. Finally, chapter four will describe 
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experiments aiming to compare and contrast the T cell phenotypes involved in 
successful and failed anti-tumor immune responses. Unless otherwise noted, the 

























Chapter Two: The Impact of B Cell Depletion on Anti-PD-1 Efficacy 
This section was written in collaboration with Wiliam Damsky, MD, PhD and Harriet 
Kluger, MD.  
 
 
Background and Hypothesis 
 The list of approved indications for immune checkpoint inhibitors continues to 
expand as clinical trials report survival benefits in patients with a variety of malignancies. 
In addition to melanoma, checkpoint inhibition has been approved to treat renal cell 
carcinoma, non-small cell lung cancer, urothelial carcinoma, cervical cancer, 
hepatocellular carcinoma, head and neck cancer, colon cancer with microsatellite 
instability, Hodgkin’s lymphoma, Merkel cell carcinoma, and urothelial carcinoma (189-
199). The excitement surrounding the benefits of these medications is somewhat offset, 
however, by the immune-mediated toxicities (irAEs) experienced by a large number of 
patients on these therapies. As discussed in chapter 1B, these irAEs can affect almost 
any organ system and range in severity from mild to life-threatening. Many of these 
toxicities are thought to result from off-target T cell activation, and they often resolve with 
the administration of corticosteroids or TNF-α inhibitors (8). Some irAEs, however, may 
be mediated or exacerbated by B cells. Indeed, there are case reports of steroid-
refractory irAEs that resolved following administration of rituximab, an anti-CD20 
antibody that depletes B cells (Figure 2.1) (171, 200-203). While retrospective analyses 
have indicated that neither steroids nor TNF-α inhibitors interfere with the anti-tumor 
immune reponse induced by immune checkpoint inhibitors, little is known about the 
impact of B cell depletion on this response (8, 204). To explore this question, we first 
used the YUMMER1.7 murine melanoma and MC38 murine colon carcinoma models to 
compare responses to anti-PD-1 therapy in the presence and absence of B cells. We 
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then compared B cell infiltration in anti-PD-1-responsive and anti-PD-1-nonresponsive 
human melanoma samples. We hypothesized that B cells are nonessential to the anti-
tumor immune response, and for this reason, their depletion would have little to no 
impact on the effects of PD-1 inhibitors.  
Figure 2.1: Reports of rituximab use in treatment of irAEs. ITP, immune 
thrombocytopenic purpura; PR, partial response; CR, complete response; PD, 




Cell lines and tissue culture  
The YUMMER1.7 melanoma model was described in chapter 1C. The MC38 
model is a syngeneic colon cancer cell line that produces immunogenic tumors when 
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injected into C57Bl/6J mice (206). All cell lines were maintained in DMEM/F12 media 
containing 10% FBS, 1% nonessential amino acids, and 1% penicillin-streptomycin. 
 
Murine models 
YUMMER1.7 and MC38 tumor cells were implanted subcutaneously into the right 
hind flanks of wildtype C57Bl/6J mice, muMT (Ighm-/-) mice deficient in B cells, and 
Rag1-/- mice deficient in both B and T cells, all from Jackson Laboratory. To form 
YUMMER1.7 tumors, 500,000 cells were implanted as described in chapter 1C. For 
spontaneous regression of YUMMER1.7 tumors, 100,000 cells were implanted as 
described in chapter 1C. To form MC38 tumors, 250,000 cells were implanted. Mice 
were euthanized according to humane endpoints when tumors reached 1.5 cm in 
maximum dimension or when tumors ulcerated. 
 
Drug treatments 
Treatment with RMP1-14, an anti-mouse PD-1 antibody from Bio X Cell, was 
initiated on post-injection day 7 when tumors were roughly 50-100 mm3 in size. Anti-PD-
1 was diluted in sterile saline and administered by intraperitoneal injection at a dose of 8 
mg/kg every 3 days for a total of 6 doses. Treatment with AISB12, an anti-mouse CD20 
antibody from Bio X Cell, was initiated on post-injection day 9 (3 days following initiation 
of anti-PD-1 therapy) and administered at a dose of 25 mg/kg in sterile saline by 
intraperitoneal injection on two consecutive days. Anti-CD20 therapy was similarly 
repeated every 2 weeks. Saline vehicle was administered to control animals. 
 
Immunohistochemistry 
At experimental endpoint, murine tumors were harvested, formalin-fixed, and 
paraffin-embedded using standard methods. Immunohistochemistry using anti-mouse 
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B220 antibody to identify CD45R (PTPRC) on the surface of B cells was performed 
using standard methods. The intratumoral B cell density (number of B220-positive cells 
per high power field) was assessed for 10 HPF per tumor, and the mean was calculated 
using 3 replicate animals per group. This was performed with the assistance of William 
Damsky, MD, PhD and Marcus Bosenberg, MD, PhD. 
 
Tumor dissociation and flow cytometry 
Tumors were minced in RPMI medium with 2% fetal bovine serum (FBS), 0.5 
mg/mL collagenase IV, and 200 mg/L DNase. They were then digested in a 37C 
incubator for 30 min and filtered to remove debris. Single-cell suspensions from tumors 
or splenocytes were incubated on ice for 15 minutes with 2.4G2, an anti-Fc receptor 
antibody. The cells were then stained with appropriate antibodies in 2.4G2-containing 
buffer. Data was acquired on an LSR II (BD Biosciences) and analyzed with FlowJo. 
LIVE/DEAD discrimination was performed using the LIVE/DEAD Fixable Red Dead Cell 
Stain Kit from Invitrogen. Antibodies against CD45 (A20) were obtained from 
eBioscience. Antibodies against CD3 (17A2), CD11b (M1/70) and CD20 (SA275A11) 
were obtained from Biolegend. Antibodies against B220 (RA3-6B2) were obtained from 
BD Biosciences. These steps were performed by William Damsky, MD, PhD and Curtis 
Perry, MD, PhD. 
 
Patients  
Tumor samples from 40 patients with advanced melanoma treated with PD-1 
inhibitors were analyzed, of which 34 were evaluable for response. Areas of invasive 
melanoma were identified and cored by a board-certified pathologist. A tissue microarray 
(TMA) was generated using methods that have been previously described, incorporating 
three cores per specimen (207, 208). Specimens and clinical information were retrieved 
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with approval of the Yale University Human Investigations Committee. Patient 
demographics are summarized in Figure 2.2.  The cohort included 70% males and 30% 
females. Age at initiation of therapy ranged from 43 to 92 with a mean of 66. At the start 
of therapy, 5% had stage M1a disease, 15% had stage M1b disease, and 80% had 
stage M1c disease. LDH was elevated in 35% of patients; BRAF, NRAS, and KIT 
mutations were found in 30%, 25%, and 5% of cases, respectively. 77.5% of patients 
had cutaneous non-acral lentiginous melanoma, 10% had acral melanoma, 10% had 
mucosal melanoma, and 2.5% had uveal melanoma. RECIST 1.1 criteria were used for 
clinical assessment and classification of response. This was performed by Harriet 
Kluger, MD and Lucia Jilaveanu, MD, PhD. 
Characteristic n % 
Age, years  
   Median 66 
   Range 43-92 
Sex  
   Male 28 70 
   Female 12 30 
Elevated LDH 14 35 
Mutation  
   BRAF 12 30 
   NRAS 10 25 
   KIT 2 5 
  GNAQ 1 0.25 
Primary melanoma type  
   Cutaneous non-acral lentiginous 31 77.5 
   Acral  4 10 
   Mucosal 4 10 
   Uveal 1 2.5 
 
Figure 2.2: Baseline characteristics of melanoma patients treated with anti-PD-1 
therapy (N=40). 
 
Immunofluorescence staining and quantification of B cell content 
Immunofluorescence staining was performed using standard methods (209, 210). 
Staining for CD20 was performed with a mouse monoclonal antibody (clone L26) from 
Dako. Tumor area was identified with a rabbit anti-S100 antibody from Dako. To 
determine the degree of tumor-infiltrating B cells, CD20-positive cells within the tumor 
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mask were counted within each histospot. Tumor spots were included if they contained 
sufficient tissue for analysis (>3% of the histospot area) and did not contain abundant 
necrotic tissue. This was performed by Lucia Jilaveanu, MD, PhD. 
 
Statistical analyses 
For murine data, Prism version 7.0 software was used. Difference in survival was 
assessed using the Kaplan-Meier method, and statistical significance was determined 
using the log-rank (Mantel-Cox) test. For human data, JMP version 5.0 software was 
used (SAS Institute, Cary, NC). The association between B cell content and objective 
response status (complete or partial response vs. stable or progressive disease) was 
assessed using t-tests.  Survival curves were constructed using the Kaplan-Meier 
method, and statistical significance was determined using the log-rank test. 
 
Results 
To determine whether B cell depletion with anti-CD20 antibodies affects the anti-
tumor efficacy of PD-1 inhibitors, we used the MC38 colon carcinoma and YUMMER1.7 
melanoma models. We first characterized baseline intratumoral B cell infiltration using 
B220 immunohistochemistry and found that B cells were present in both models. In 
YUMMER1.7 tumors, B cells tended to cluster in aggregates at the edges, whereas B 
cells were distributed fairly evenly throughout MC38 tumors (Figure 2.3A-D).  
40 mice with established MC38 tumors were divided into four treatment groups 
with 10 mice per group: control, anti-CD20 alone, anti-PD-1 alone, and anti-CD20 + anti-
PD-1. They began receiving anti-PD-1 therapy on post-injection day 7, followed 2 days 
later by anti-CD20 therapy with AISB12, an antibody that has been shown to effectively 
deplete murine B cells in blood, spleen, bone marrow and other tissues (211-213). As 
shown in the Kaplan-Meier curves in Figure 2.4A, survival did not differ when anti-CD20 
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antibodies were added to anti-PD-1 therapy. Moreover, survival did not differ between 
mice treated with anti-CD20 antibodies alone and control mice, further supporting the 
hypothesis that B cells are not required for effective anti-tumor immune responses 
induced by PD-1 inhibition. Tumor volumes for these four cohorts of mice are shown by 
waterfall plots in Figure 2.4B and spider plots in Figure 2.5A.  
Another 40 mice with established YUMMER1.7 tumors were divided into the 
same four treatment groups used in the previous experiment. As with the MC38 
experiment, we showed that anti-CD20 antibodies neither affect tumor growth or survival 
nor impair the anti-tumor effect induced by PD-1 inhibitors (Figures 2.4C, 2.4D, and 
2.5B). As shown in Figures 2.3E and 2.3F, anti-CD20 antibodies were effective in 
reducing B cell infiltrate in both tumor and spleen. Importantly, there were no signs of 
distress in any of the animals treated with anti-CD20 antibodies; weight and activity 
levels were maintained throughout the experiment. 
To further test the hypothesis that B cell activity is dispensable for effective anti-
tumor immune responses induced by PD-1 inhibition, we employed muMT mice that lack 
B cells due to biallelic inactivation of the Ighm gene that encodes the IgM heavy chain 
(214). We first tested the ability of muMT mice to spontaneously reject YUMMER1.7 
cells as described in chapter 1C. When 100,000 YUMMER1.7 cells were injected into 
muMT host animals, they were able to reject YUMMER1.7 cells as efficiently as 
C57Bl/6J control animals. Rag1-/- mice were also included as controls and failed to reject 
100,000-cell injections (Figure 2.6A). We then assessed the effect of B cell deficiency in 
the setting of immunotherapy by treating both wildtype and muMT mice bearing MC38 
tumors with PD-1 inhibitors. There was no difference in survival between these groups 
(Figure 2.6B). Taken together, these data suggest that while T cells are required for 
immune-mediated rejection of YUMMER1.7 tumors, B cells are not. 
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Figure 2.3: B cells in MC38 and YUMMER1.7 tumors. A. Tumor-infiltrating B cell 
density in MC38 tumors. B. Quantification of A. C. Tumor-infiltrating B cell density in 
YUMMER1.7 tumors. D. Quantification of C. E. Quantification of flow cytometry 
experiments showing number of CD20+ cells in spleen (shown as percentage of all 
lymphocytes). F. Quantification of flow cytometry experiments showing number of 














Figure 2.4: Anti-CD20 antibody therapy does not affect anti-tumor immune 
responses in murine models of colon cancer (MC38) and melanoma (YUMMER1.7). 
A. Survival of MC38 tumor-bearing mice treated with saline (ctrl), anti-CD20, anti-PD-1, 
or anti-CD20 + anti-PD-1 (comb). Ctrl vs. CD20 p=0.78; PD-1 vs. comb p=0.67; ctrl + 
comb p<0.0001. B. Waterfall plot of groups in A. C. Survival of YUMMER1.7 tumor-
bearing mice treated with saline (ctrl), anti-CD20, anti-PD-1, or anti-CD20 + anti-PD-1 
(comb). Ctrl vs. CD20 p=0.08; PD-1 vs. comb p=0.73; ctrl + comb p=0.0008. D. Waterfall 










Figure 2.5: Anti-CD20 antibody therapy does not affect anti-tumor immune 
responses in murine models of colon cancer (MC38) and melanoma (YUMMER1.7). 
A. Spider plots showing MC38 tumor growth in individual mice from Figures 2.4A and 
2.4B. B. Spider plots showing YUMMER1.7 tumor growth in individual mice from Figures 















Figure 2.6: B cell deficiency does not impair anti-tumor immune responses in 
murine models of colon cancer (MC38) and melanoma (YUMMER1.7). A. Survival of 
mice after implantation of 100,000 YUMMER1.7 cells. C57Bl/6J (B6) vs. muMT 
p=0.7319. muMT vs. Rag1-/- p<0.0001. B. Survival of MC38 tumor-bearing mice treated 
with anti-PD-1. C57Bl/6J (B6) vs. muMT p=0.1435. 
 
Tumor samples from 40 melanoma patients were analyzed, and B cells were 
quantified in each. Tumor-infiltrating B cells were fairly sparse in most samples, ranging 
from 0-131 cells per 0.6 mm histospot with a median of 2.5 B cells and a mean of 17.4 B 
cells. Examples of heavily and poorly infiltrated tumors are shown in Figure 2.7 A and B, 
respectively. 34 of the 40 patients in this cohort were evaluable for response, and the 
objective response rate to PD-1 inhibitors by RECIST1.1 criteria was 32%. As shown in 
Figure 2.8A, there was no association between B cell content and response. Using the 
Cox Proportional Hazards method, we found no association between B cell content and 
progression-free or overall survival (p=0.18 and p=0.64, respectively). We categorized 
tumors as B cell-rich or B cell-poor based on whether their B cell content was greater 
than or less than the median and found no significant difference in progression-free 
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survival (P=0.18) or overall survival (P=0.64) among the groups by log rank statistics 
(Figure 2.8B-C). 
 
Figure 2.7. Examples of B cell-rich (A) and B cell-poor (B) tumors. Tumor is masked 
by a cocktail of antibodies to S100 and HMB45 conjugated to Cy2 (green), and the area 
of B cell infiltrate is determined by the relative area of CD20-positive cells within the 
tumor mask, identified by anti-CD20 antibodies conjugated to Cy5 (red). Nuclei are 
















Figure 2.8. Tumor-infiltrating B cell density is not associated with response to 
anti-PD1 therapy. A. B cell quantification in responders (CR: complete response, PR: 
partial response) (n=11) vs. non-responders (SD: stable disease, PD: progressive 
disease) (n=23), p=0.22. B. Presence or absence or tumor-infiltrating B cells does not 
correlate with progression free survival, p=0.18. C. Presence or absence of tumor-
infiltrating B cells does not correlate with overall survival, p=0.64. 
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Discussion 
We utilized two murine models to determine the effect of B cell-depleting 
antibodies on tumor control in the setting of PD-1 inhibition and showed that the addition 
of antibodies targeting CD20 to anti-PD-1 therapy has no effect on tumor growth or 
animal survival. We additionally showed that mice deficient in B cells neither exhibited a 
defect in spontaneous immune-mediated tumor rejection nor a defect in anti-PD-1 
response. In contrast, mice deficient in both B and T cells (Rag1-/-) had unabated tumor 
growth. Furthermore, we showed that human melanomas tend to have limited B cell 
infiltration and that the quantity of B cells in human tumors does not correlate with 
response to therapy, progression-free survival, or overall survival.  
We aimed to determine whether B cell depletion is a safe approach to treatment 
of irAEs caused by PD-1 inhibitors and whether this would impair their anti-tumor 
activity. While the importance of tumor-infiltrating T cells in anti-tumor immunity is 
indisputable, the role of B cells is less clear. Like T cells, the B cell lineage includes 
subsets that may be tumor-promoting and others that could inhibit tumor growth (215). 
For instance, the presence of IgA+ plasmablasts expressing PD-L1 and secreting IL-10 
has been shown to render prostate cancer refractory to cytotoxic T lymphocyte-
dependent eradication (216). In contrast, autoantibodies to a variety of melanoma 
antigens have been shown to correlate with improved outcomes, higher tumor-infiltrating 
CD8+ lymphocyte counts, and a greater likelihood of response to ipilimumab (217). B 
cells might play a role in the tumor micro-environment beyond secretion of auto-
antibodies; they can modulate T cell responses either directly by presenting antigens 
and activating T cells or indirectly through the formation of antigen-antibody immune 
complexes that can activate myeloid and/or antigen presenting cells expressing Fc 
receptors in the tumor microenvironment (218, 219). Murine squamous cell carcinoma 
growth was shown to be reduced in B cell-deficient compared to wildtype mice, and 
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injection of B cell-depleting antibodies in wildtype mice resulted in enhanced tumor 
infiltration by CD8+ T cells (220). In addition, there is improved prognosis when B cells 
are found in proximity to CD8+ T cells in the tumor microenvironments of ovarian tumors 
(221). Despite these findings, however, it is unclear whether the immune-stimulating 
effects of B cells are clinically meaningful in the setting of metastatic melanoma treated 
with immune checkpoint inhibitors. Our data show a lack of association between 
intratumoral B cell content and response to PD-1 inhibitors in human samples, 
suggesting that B cells do not play a major role in anti-tumor immunity in the setting of 
PD-1 inhibitor therapy. Instead, anti-tumor immunity may rely mostly on T cell 
disinhibition or Treg depletion, leading to the activation of effector T cells targeting the 
tumor.  
Since anti-CD20 antibodies such as rituximab are currently the primary modality 
for depleting B cells, we tested anti-CD20 antibodies in two murine tumor models. The 
first is the MC38 colon cancer model, which is relatively sensitive to immune checkpoint 
inhibitors, including both those targeting PD-1 and CTLA-4 (206). We also employed the 
UV-mutagenized, neoantigen-rich YUMMER1.7 cell line as a second murine cancer 
model. As shown in chapter 1C, these cells are partially sensitive to PD-1 inhibition since 
anti-PD-1 treatment results in both complete and partial responses in mouse subsets 
(187). We showed that B cell inhibition with anti-CD20 antibodies does not impair the 
anti-tumor immune response induced by PD-1 inhibition in either model. This lends 
preclinical support for the use of anti-CD20 antibodies to treat steroid-refractory irAEs in 
patients with good-to-moderate clinical responses or stable disease. 
Our third murine approach using the spontaneous regression model of 
YUMMER1.7 in muMT mice provides further evidence that the use of therapies targeting 
B cells is warranted in patients that may require them for autoimmune toxicities induced 
by immune checkpoint inhibitors. muMT mice, which lack B cells due to biallelic 
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inactivation of the Ighm gene, reject tumor cells as efficiently as wildtype mice. We 
tested the efficacy of anti-PD-1 therapy in muMT mice using MC38 cells and found no 
statistically significant difference in survival compared to wildtype C57Bl/6J mice. We 
therefore conclude that B cells are not required for either endogenous or anti-PD-1-
elicited anti-tumor immune responses in C57Bl/6J mice.  
 As immune checkpoint inhibitors are gaining approval for the treatment of 
multiple tumor types, the incidence of autoimmune toxicities is likely to rise, and 
previously undescribed adverse events, such as fulminant myocarditis, have only 
recently been reported (222). Some of these toxicities, such as autoimmune hemolytic 
anemia and bullous pemphigoid, are known to be antibody-mediated and may be more 
likely to respond to rituximab (171). Other toxicities, such as type I diabetes, rheumatoid 
arthritis, and multiple sclerosis, are thought to be predominantly T cell-mediated, 
although clinical trials of anti-B cell therapy in both rheumatoid arthritis and multiple 
sclerosis have shown some efficacy, further supporting the use of anti-CD20 antibodies 
for irAEs (223). Several groups have already reported successful use of rituximab for the 
treatment of certain irAEs induced by both ipilimumab and nivolumab (Figure 2.1) (171, 
200-203, 205). 
Patients with underlying autoimmune disorders who require immune therapy for 
malignancies pose an additional challenge. To date, these patients have not been 
formally studied, and the safety of immune checkpoint inhibitors in this setting remains 
unclear. Case series suggest that immunotherapy may be unsafe in a subset of these 
patients (224). Once immune checkpoint inhibitors are initiated in patients with 
underlying autoimmunity, their diseases often flare, and additional adverse events can 
be seen. Given that rituximab therapy is already entertained for certain autoimmune 
disorders such as multiple sclerosis (225), our results support studying the use of 
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The experiments described in this chapter provide evidence that tumor-infiltrating 
B cells are not required for effective immune checkpoint inhibitor-induced anti-tumor 
immune response. We first used animal models of melanoma and colon carcinoma to 
demonstrate that neither B cell depletion nor deficiency affect tumor growth and overall 
survival in mice treated with PD-1 inhibitors. We then used human melanoma samples to 
show that there is no association between the density of tumor-infiltrating B cells and 
response to PD-1 inhibitors. Taken together, these studies support further research into 
the use of B cell-inhibiting therapies both in patients who develop steroid-refractory irAEs 















Chapter Three: Myeloid and T Cell-Targeted Immunotherapies Synergize and 
Result in Durable Tumor Remission in Multiple Murine Cancer Models 
 
 
Background and Hypothesis 
 Immune checkpoint inhibitors have revolutionized the management of metastatic 
melanoma, offering increased progression-free and overall survival when compared to 
both chemotherapy and targeted therapies. As discussed in chapter 1B, however, only a 
subset of melanoma patients respond to immune checkpoint inhibition, and a significant 
proportion of those who do respond will go on to develop acquired resistance to these 
medications. One proposed mechanism for this resistance involves myeloid-derived 
elements of the tumor microenvironment including tumor associated macrophages 
(TAM), tumor-associated neutrophils (TAN), and myeloid-derived suppressor cells 
(MDSC) (8). On the one hand, TAMs can function to enhance immune responses 
through antigen presentation and direct cytotoxicity, consistent with the classical, pro-
inflammatory M1 phenotype (226). On the other hand, however, TAMs may favor tumor 
progression through a number of functions including secretion of pro-proliferative factors 
such as insulin-like growth factor (IGF), pro-angiogenic factors such as VEGF and 
platelet-derived growth factor (PDGF), and pro-invasive factors such as matrix 
metalloproteinases (MMP) (227). They are also thought to inhibit anti-tumor immune 
responses through release of immunosuppressive cytokines including IL-10 and TGFβ, 
among others, consistent with the more anti-inflammatory M2 phenotype (228, 229). 
Indeed, as described with YUMM tumors in chapter 1C, human melanomas with sparse 
TILs yet dense TAMs are poorly responsive to immune checkpoint inhibitor therapy 
(230).  
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 Given that these myeloid elements have the potential to both help and hinder 
tumor formation, there is much interest in interventions that may push these cells toward 
a more tumor-suppressive phenotype. One such intervention involves blockade of 
colony-stimulating factor-1 receptor (CSF-1R), a receptor that promotes the proliferation 
and maturation of monocytes and their derivatives when bound to its ligand, CSF-1 
(231). Blockade or deletion of CSF-1R has been shown to reduce TAMs (232, 233) and 
improve therapeutic responses in both animal tumor models and human tumors (234, 
235). Another possible intervention involves treatment with agonistic antibodies to CD40, 
a stimulatory receptor expressed on B cells, macrophages, and dendritic cells that 
enhances antigen presentation (236, 237). CD40 agonism has been shown to reduce 
resistance to immune checkpoint inhibition in human tumors (236) and to increase 
expression of MHC molecules, co-stimulatory molecules, and proinflammatory cytokines 
including IFNγ by TAMs (238).  
 We aimed to assess the impact of these myeloid-targeting therapies on the 
immune checkpoint inhibitor-induced anti-tumor immune response. To explore this 
question, we used the YUMMER1.7 murine melanoma and RENCA murine renal cell 
carcinoma models to determine the effect of supplementing PD-1 inhibition with CD40 
agonism and/or CSF-1R antagonism. We additionally assessed the effects of triple anti-
PD-1/CD40 agonist/CSF-1R antagonist therapy on tumors formed from YUMMER1.7 
cells deficient in either the IFNγ receptor (IFNγR) or β2 microglobulin (β2M), a necessary 
component of the MHC class I molecule that is upregulated downsteam of IFNγR 
activation (239). We hypothesized that tumor regression and survival would be greater in 
mice treated with triple therapy than in those treated with double therapy, monotherapy, 
or control therapy. We further hypothesized that treatment with triple therapy would 
correspond to increased secretion of pro-inflammatory cytokines. Finally, we 
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hypothesized that mice bearing tumors deficient in IFNγR or β2M would fail to exhibit 
increased survival over control conditions when treated with triple therapy. 
 
Methods 
Cell lines and tissue culture  
The YUMMER1.7 melanoma model was described in chapter 1C. IFNγR-
deficient and β2M-deficient YUMMER1.7 lines were generated using CRISPR/Cas9-
mediated gene deletion. The RENCA line was derived from a renal cortical 
adenocarcinoma that arose spontaneously in a BALB/c mouse (240). The YUMMER1.7 
lines were maintained in DMEM/F12 media containing 10% FBS, 1% nonessential 
amino acids, and 1% penicillin-streptomycin. The RENCA lines were maintained in 
RPMI-1640 media with 10% FBS, 1% nonessential amino acids, 1% penicillin-
streptomycin, 1% sodium pyruvate, and 1% L-glutamine. 
 
Murine models 
Wildtype YUMMER1.7, IFNγR-deficient YUMMER1.7, and β2M-deficient 
YUMMER1.7 tumor cells were implanted subcutaneously into the right hind flanks of 
wildtype C57Bl/6J mice from Jackson Laboratory. RENCA tumor cells were implanted 
subcutaneously into the right hind flanks of wildtype BALB/c mice from Jackson 
Laboratory. To form tumors from wildtype YUMMER1.7 or IFNγR-deficient YUMMER1.7 
cells, 500,000 cells were implanted as described in chapter 1C. To form tumors from 
β2M-deficient YUMMER1.7 cells, 1,000,000 cells were implanted. To form RENCA 
tumors, 500,000 cells were implanted. Mice were euthanized according to humane 





Treatments were initiated on post-injection day 7 when tumors were roughly 50-
100 mm3 in size and were administered twice weekly for a total of 6 doses. Treatment 
with anti-PD-1 antibody (RMP1-14, Bio X Cell) was administered at a dose of 8 mg/kg in 
sterile saline by intraperitoneal injection. Treatment with anti-CD40 agonist antibody 
(FGK4.5, Bio X Cell) was administered at a dose of 8 mg/kg in sterile saline by 
intraperitoneal injection. Treatment with anti-CSF-1R antibody (mCSF1R.2-mG1, Bristol-
Myers Squibb) was administered at a dose of 8 mg/kg in sterile saline by intraperitoneal 
injection. Saline vehicle was administered to control animals. 
 
Cytokine analysis 
 Blood was obtained via retro-orbital collection into heparinized rubes on day 2 of 
treatment. Plasma was prepared and stored at -80C. Cytokine levels in plasma were 
determined using the Mouse Cytokine Array 31-Plex by Eve Technologies.  
 
Statistical analyses 
Prism version 7.0 software was used. Difference in survival was assessed using 
the Kaplan-Meier method, and statistical significance was determined using the log-rank 
(Mantel-Cox) test.  
 
Results 
80 mice with established YUMMER1.7 tumors were divided into eight treatment 
groups with 10 mice per group: control, anti-PD-1, anti-CD40, anti-CSF-1R, anti-PD-1 + 
anti-CD40, anti-PD-1 + anti-CSF-1R, anti-CD40 + anti-CSF-1R, and anti-PD-1 + anti-
CD40 + anti-CSF-1R. As shown in the Kaplan-Meier curves in Figure 3.1A, survival did 
not significantly differ among control mice and those treated with anti-PD-1 or anti-CSF-
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1R monotherapy. Survival was significantly increased, however, in mice treated with 
anti-CD40 relative to control mice. Supplementing anti-CD40 with anti-CSF-1R resulted 
in increased survival, although this effect did not reach statistical significance in this 
study. Survival was also significantly increased in mice treated with either anti-CD40 + 
anti-CSF-1R or anti-PD-1 + anti-CD40 + anti-CSF-1R relative to both control mice and 
those receiving anti-PD-1 alone. Survival did not increase significantly when anti-PD-1 
was added to anti-CD40 + anti-CSF-1R. Tumor volumes for the control, anti-PD-1, anti-
CD40 + anti-CSF-1R, and anti-PD-1 + anti-CD40 + anti-CSF-1R groups are shown by 
spider plots in Figure 3.2A.  
Another 40 mice with established RENCA tumors were divided into four 
treatment groups with 10 mice per group: control, anti-PD-1, anti-CD40 + anti-CSF-1R, 
and anti-PD-1 + anti-CD40 + anti-CSF-1R. As with the YUMMER1.7 experiment, we 
showed that survival did not significantly differ among control mice and those treated 
with anti-PD-1 monotherapy. Survival was significantly increased, however, in mice 
treated with either anti-CD40 + anti-CSF-1R or anti-PD-1 + anti-CD40 + anti-CSF-1R 
relative to both control mice and those receiving anti-PD-1 alone. Survival did not 
increase significantly when anti-PD-1 was added to anti-CD40 + anti-CSF-1R. The 
survival and growth curves are shown in Figures 3.1B and 3.2B, respectively. 
To explore whether IFNγ signaling is required for the effect of triple therapy on 
tumor growth, we performed a pilot experiment in which 6 mice with established IFNγR-
deficient YUMMER1.7 tumors and 6 mice with established β2M-deficient YUMMER1.7 
tumors were divided into two treatment groups containing 3 mice per group: control and 
anti-PD-1 + anti-CD40 + anti-CSF-1R. Prior experiments have demonstrated that 
treatment with anti-PD-1 monotherapy does not significantly increase survival in mice 



















Figure 3.1: Supplementing anti-PD-1 therapy with CD40 agonist and CSF-1R 
antagonist increases survival in murine models of melanoma (YUMMER1.7) and 
renal cell carcinoma (RENCA). A. Survival of YUMMER1.7 tumor-bearing mice treated 
with saline (ctrl), anti-PD-1, anti-CD40, anti-CSF-1R, anti-PD-1 + anti-CD40, anti-PD-1 + 
anti-CSF-1R, anti-CD40 + anti-CSF-1R, or anti-PD-1 + anti-CD40 + anti-CSF-1R. Ctrl vs. 
anti-PD-1 p=0.11; Ctrl vs. anti-CD40 p=0.0001; Ctrl vs. anti-CSF-1R p=0.33; Ctrl vs. anti-
CD40 + anti-CSF-1R p<0.0001; Ctrl vs. anti-PD-1 + anti-CD40 + anti-CSF-1R p<0.0001; 
anti-PD-1 vs. anti-CD40 + anti-CSF-1R p=0.0022; anti-PD-1 vs. anti-PD-1 + anti-CD40 + 
anti-CSF-1R p<0.0001; anti-CD40 vs. anti-CD40 + anti-CSF-1R p = 0.079; anti-CD40 + 
anti-CSF-1R vs. anti-PD-1 + anti-CD40 + anti-CSF-1R p=0.23. B. Survival of RENCA 
tumor-bearing mice treated with saline (ctrl), anti-PD-1, anti-CD40 + anti-CSF-1R, or 
anti-PD-1 + anti-CD40 + anti-CSF-1R. Ctrl vs. anti-PD-1 p=0.55; Ctrl vs. anti-CD40 + 
anti-CSF-1R p=0.0054; Ctrl vs. anti-PD-1 + anti-CD40 + anti-CSF-1R p=0.0004; anti-PD-
1 vs. anti-CD40 + anti-CSF-1R p=0.013; anti-PD-1 vs. anti-PD-1 + anti-CD40 + anti-


























Figure 3.2: Supplementing anti-PD-1 therapy with CD40 agonist and CSF-1R 
antagonist increases survival in murine models of melanoma (YUMMER1.7) and 
renal cell carcinoma (RENCA). A. Spider plots showing YUMMER1.7 tumor growth in 
individual mice from Figure 3.1A. B. Spider plots showing RENCA tumor growth in 
individual mice from Figure 3.1B. 
YUMMER1.7 RENCA A B 
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Kaplan-Meier curves in Figure 3.3, however, survival is significantly increased in mice 
receiving anti-PD-1 + anti-CD40 + anti-CSF-1R relative to those receiving control 
treatment for mice bearing both IFNγR-deficient (A) and β2M-deficient tumors (B). 





















Figure 3.3: Triple therapy increases survival in mice bearing IFNγ-nonresponsive 
tumors. A. Survival of mice bearing IFNγR-deficient YUMMER1.7 tumors treated with 
saline (ctrl) or anti-PD-1 + anti-CD40 + anti-CSF-1R. p=0.022 B. Survival of mice bearing 




















Figure 3.4: Triple therapy slows tumor growth in mice bearing IFNγ-nonresponsive 
tumors. A. Spider plots showing IFNγR-deficient YUMMER1.7 tumor growth in 
individual mice from Figure 3.3A. B. Spider plots showing β2M-deficient YUMMER1.7 
tumor growth in individual mice from Figure 3.3B. 
 
  
Figure 3.5 shows cytokine levels in mice receiving the various treatments. Blood 
from mice that received CD40 agonist either as monotherapy or in combination with 
other treatments contained significantly higher levels of G-CSF, IFNγ, TNFα, IL-6, IL-16, 
CCL2, CCL5, CXCL1, CXCL9, CCL17, CCL19, CCL20, CCL22, and TIMP1 when 
compared to blood from mice that did not receive CD40 agonist. Additionally, levels of 
IL-10 and IL-12 were significantly elevated in blood from mice treated with CD40 agonist 
monotherapy, CD40 agonist/CSF-1R antagonist dual therapy, and triple therapy (but not 
anti-PD-1/CD40 agonist dual therapy) when compared to those treated with control, 
A 
B 



















α-PD1 + α-CD40 + α-CSF1R



















α-PD1 + α-CD40 + α-CSF1R
	 64	
CSF-1R monotherapy, or anti-PD-1 monotherapy. Levels of CXCL10 were significantly 
increased in mice receiving triple therapy relative to those receiving all other therapies. 
The levels of GM-CSF, IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-7, IL-9, IL-13, IL-15, IL-17, 
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Figure 3.5: Cytokine concentrations in peripheral blood. Error bars represent 95% 
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We employed murine models of two tumors commonly treated with immune 
checkpoint inhibitors - melanoma and renal cell carcinoma – to assess the potential for 
myeloid-targeting therapies to supplement the anti-tumor immune responses induced by 
PD-1 inhibition. In both models, triple therapy with PD-1 inhibition, CD40 agonism, and 
CSF-1R antagonism resulted in increased survival relative to both control therapy and 
monotherapy with PD-1 inhibition. In fact, as shown by the growth curves in Figure 3.2, 
the majority of tumors treated with triple therapy regressed completely, in stark contrast 
to those treated with anti-PD-1 monotherapy.  
We did not, however, observe a significant survival advantage in mice treated 
with triple therapy relative to those treated with anti-CD40 + anti-CSF-1R, suggesting 
that the contribution of PD-1 inhibition to the increases in survival seen with triple 
therapy is minimal. This may be explained by the fact that both tumor lines employed in 
this study are relatively insensitive to anti-PD-1 monotherapy (Figures 3.1 and 3.2), a 
property shared by a significant proportion of melanomas and other typically 
immunogenic cancers. Our observation that triple therapy increases survival over PD-1 
monotherapy in these models therefore lends support to the idea that myeloid-targeted 
therapies may show promise in treating patients with immune checkpoint inhibitor-
resistant tumors. It should also be noted that the difference in survival, particularly in the 
YUMMER1.7 model, may have reached significance with larger sample sizes or a longer 
window of observation, as complete tumor regression was more commonly observed in 
mice treated with the triple therapy than with anti-CD40 + anti-CSF-1R therapy (Figure 
3.2). 
We additionally observed that triple therapy enhances survival even in mice 
bearing tumors that are unable to transduce IFNγ signaling, challenging the notion that 
IFNγ is necessary for T cell-mediated tumor killing. It is possible that T cells may be 
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engaged through an IFNγ-independent mechanism that becomes upregulated in the 
presence of CD40 agonist and CSF-1R antagonist. This is unlikely, however, as Perry, 
et al. showed that antibody-mediated IFNγ blockade eliminates the anti-tumor effects of 
double therapy (241). Importantly, none of the YUMMER1.7 tumors deficient in IFNγR or 
β2M completely regressed, and only one mouse bearing an IFNγR-deficient tumor 
survived to the end of the observation window, at which point its tumor was growing 
rather than regressing. The increased survival observed when treating IFNγR or β2M-
deficient tumors with triple therapy was thus due to slowed tumor growth instead of 
tumor regression. One explanation for this effect is that myeloid cell stimulation may 
promote a burst of local inflammation that perturbs initial tumor growth. In order to better 
define this growth phenotype, we plan to repeat these experiments using larger cohorts 
and an extended observation period.  
Given the potential utility of these myeloid therapies in treating immune 
checkpoint inhibitor-resistant tumors, it will be important to define the cellular 
mechanisms responsible for the observed survival benefits. Perry, et al. used combined 
CD40 agonist and CSF-1R antagonist to treat melanomas derived from the poorly 
immunogenic BRAFV600E/PTEN-/- GEMM discussed in chapter 1C (241). This 
combination therapy was found to suppress tumor growth despite increasing the density 
of TAMs. Analysis of RNA transcription revealed that monotherapy with CD40 agonist 
increased TAM expression of Tnfa, Ifng, Il12b, and Cxcl9, all genes encoding pro-
inflammatory cytokines, while monotherapy with CSF-1R antagonist reduced expression 
of Cd36 and Fabp4, genes involved in lipid homeostasis. Single-cell secretion profiling 
revealed that TAMs from dual-treated tumors exhibited increased secretion of M1-type 
cytokines including TNFα, IL-6, IL-12, CCL3, CXCL1, and IFNγ and reduced secretion of 
the M2-type factor, MMP9. Additionally, this shift in TAM phenotype was shown to 
induce increased secretion of IFNγ by tumor-infiltrating T cells. Importantly, the anti-
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tumor effects of dual therapy were abrogated by T cell depletion and antibody-mediated 
blockade of TNFα or IFNγ (241).  
Wiehagen, et al. similarly employed dual CD40 agonist/CSF-1R antagonist 
therapy to treat murine tumors formed from injected MC38 or CT26 colon carcinoma 
cells (242). As observed by Perry et al., dual therapy was shown to suppress tumor 
growth in a T cell-dependent fashion, and TAMs were shown to shift their expression 
profiles toward a more pro-inflammatory phenotype. This included upregulation of co-
stimulatory molecules and inflammatory cytokines including TNFα, IL-6, IL-12, IL-23, 
GM-CSF and IFNγ. In addition, both tumor antigen-specific T cells and CD103+ dendritic 
cells that are known to cross-present tumor antigens to T cells were shown to 
accumulate more in the draining lymph nodes of dual therapy-treated mice than in 
monotherapy-treated or control mice. Finally, dual treatment was found to increase both 
the density of CD8+ TILs and the effector function of these TILs. Taken together, the 
results of these two studies elicit a model of tumor suppression in which CD40 agonism 
and CSF-1R inhibition shift TAM expression profiles toward a more pro-inflammatory 
phenotype, thereby facilitating tumor killing by T cells. 
Our findings are in concert with those of Perry, et al. and Wiehagan, et al., 
demonstrating that double therapy with CD40 agonist/CSF-1R antagonist results in 
increased secretion of proinflammatory cytokines and an improved anti-tumor immune 
response. We further demonstrate that combining myeloid-targeted therapy with PD-1 
blockade increases survival relative to PD-1 monotherapy. Treatment with CD40 agonist 
was found to upregulate cytokines associated with acute inflammation including G-CSF, 
IL-6, and TNFα, as well as cytokines associated with chemotaxis of activated T cells, 
including IL-16, CCL5, CXCL9, CCL17, CCL19, CCL20, and CCL22. Increased levels of 
IL-12 and IFNγ were also observed with CD40 agonist therapy, suggesting that its anti-
tumor effects may be partially mediated by the promotion of TH1 differentiation, as has 
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been previously described in the literature (243). Interestingly, levels of IL-10, a 
classically anti-inflammatory cytokine, were also observed to increase in mice treated 
with CD40 agonist. This effect was abrogated, however, by co-treatment with an IL-6 
receptor antagonist (data not shown), suggesting that IL-6 may play a role in engaging 
anti-inflammatory components of the tumor microenvironment including regulatory T 
cells (244).  
Our analysis also revealed that CD40 agonist therapy upregulates the MMP 
inhibitor, TIMP1. In addition to its canonical role as a regulator of extracellular matrix 
catabolism, TIMP1 has also been shown to promote cell growth and division through 
several mechanisms including mitogen activation and inhibition of MMP-mediated 
growth factor receptor shedding from cell surfaces (245). TIMP1 is often overexpressed 
in tumor tissue relative to normal tissue (246-248), and it may impair immune clearance 
of tumor cells by enhancing IL-10 expression (249). Given this potential for TIMP-1 to 
promote tumor growth, it will be important to further elucidate its role in the growth 
phenotype observed with CD40 agonist therapy.  
Treatment with anti-PD-1 monotherapy was not associated with significant 
increases in IL-2, IFNγ, or TNFα, a finding that mirrors the lack of a significant survival 
benefit in mice treated with anti-PD-1 monotherapy relative to control mice. This lends 
further support to the use of the YUMMER1.7 and RENCA cell lines to model tumors 
resistant to immune checkpoint inhibitor therapy. The addition of anti-PD-1 to CD40 
agonist/CSF-1R antagonist dual therapy, however, resulted in significant upregulation of 
CXCL10, a cytokine that promotes monocyte, NK cell, and T cell chemotaxis while 
inhibiting angiogenesis (250). Signaling via CXCL10 may therefore explain the trend 
toward increased survival in mice receiving triple therapy relative to those receiving dual 
therapy. In order to better define the changes in gene expression occurring in myeloid 
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and T cells when double therapy is added to PD-1 blockade, we are pursuing single cell 
RNA sequencing using tumor samples from the various treatment groups.   
 
Conclusion 
In summary, the experiments detailed in this chapter demonstrate that 
supplementing PD-1 inhibition with CD40 agonist and CSF-1R antagonist significantly 
increases survival relative to anti-PD-1 monotherapy in mice bearing immune checkpoint 
inhibitor-resistant melanoma and renal cell carcinoma tumors. Dual therapy with CD40 
agonist and CSF-1R antagonist leads to upregulation of cytokines that promote acute 
inflammation, T cell chemotaxis, and TH1 differentiation, while triple therapy with CD40 
agonist, CSF-1R antagonist, and PD-1 inhibition uniquely upregulates CXCL10, a 
cytokine that promotes both lymphoid and myeloid chemotaxis and attenuates 
angiogenesis. Taken together, these studies support further research into the safety and 
efficacy of adding CD40 agonist and CSF-1R antagonist to the treatment regimens of 
patients with immune checkpoint inhibitor-resistant tumors. 
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Chapter Four: Tumor Resection and Rechallenge as a Model for Failed and 
Successful Anti-tumor Immune Responses 
 
 
Background and Hypothesis  
Melanomas are highly immunogenic neoplasms, as evidenced by their 
propensity to become infiltrated by T cells and, in some cases, to spontaneously 
regress. Despite this, only 50-60% of patients with metastatic melanoma respond to 
combined anti-PD-1/anti-CTLA-4 therapy (8). Chapter three discussed the role of 
immunosuppressive elements of the tumor microenvironment in the immune system’s 
inability to control tumor progression in this subset of nonresponders. Another proposed 
explanation for this failure, however, involves acquired T cell dysfunction in the setting of 
prolonged antigen exposure, as has been described in the setting of chronic viral 
infections (251). Indeed, TILs often produce low levels of effector cytokines and express 
many of the same inhibitory receptors found on virally exhausted T cells (252-254).  
To elucidate the role of T cell dysfunction in the progression of melanoma 
specifically, it will be crucial to contrast T cell functionality in successful and failed anti-
melanoma immune responses within individual organisms. To address this need, we 
developed a model involving resection of YUMMER1.7 tumors and subsequent 
rechallenge with YUMMER1.7 cells. Pilot studies suggest that the cells injected during 
these rechallenges are rejected through a memory response. Based on these studies 
and on data presented in the previous chapter, we believe that immunosuppressive 
elements in the tumor microenvironment play a larger role in melanoma’s resistance to 
immunotherapy than does T cell dysfunction. Thus, we hypothesized that injecting mice 
with large numbers of YUMMER1.7 cells subsequent to resection of preformed 
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Cell lines and tissue culture  
YUMMER1.7 cells expressing green fluorescent protein (GFP) fused to histone 
2B (H2B) were generated using a lentivirus vector via standard methods (255). Multiple 
resulting sublines were evaluated, and one line that exhibited growth properties and 
immunogenicity similar to wildtype YUMMER1.7 cells was selected and expanded. Cell 
lines were maintained in DMEM/F12 media containing 10% FBS, 1% nonessential 
amino acids, and 1% penicillin-streptomycin. 
 
Murine models 
YUMMER1.7-H2B-GFP tumor cells were implanted subcutaneously into the right 
hind flanks of wildtype C57Bl/6J mice from Jackson Laboratory. To form tumors, 
500,000 cells were implanted. For spontaneous rejection, 50,000 cells were implanted. 
To generate mice that could launch memory responses, 100,000 cells were implanted 
and rejected as described in chapter 1C. Mice were euthanized according to humane 
endpoints if tumors reached 1.5 cm in maximum dimension or became ulcerated. 
 
Surgeries 
 Surgeries were performed on day 12 post-injection. Tumor-bearing mice were 
anesthetized using a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine 
administered by intraperitoneal injection. Vaseline was applied to the eyes to prevent 
corneal damage. Skin surrounding the tumors was shaved and cleaned three times with 
ethanol. Autoclaved forceps and surgical scissors were used to resect tumors and 
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undermine the surrounding skin. Incisions were sutured using 4-0 fast absorbing plain 
gut, and surgical glue was applied over sutures to provide extra support. Post-operative 
analgesia was provided with 2 mg/kg meloxicam solution administered by intraperitoneal 
injection. Adequate anesthesia was assessed throughout the procedure using toe 
pinching. Post-operative mice were housed in single-occupancy cages with Space Gels 
placed underneath to provide thermal support. Mice were continually monitored until 
they recovered from anesthesia and once daily afterwards. Wound dehiscence prompted 
immediate repair or euthanasia. Mock surgeries were performed on post-injection day 1 
using the protocols described above. 3 cm incisions were made in a rostral-to-caudal 
direction over the left (non-tumor bearing) hind flank.  
 
Memory timecourse 
Mice that had previously rejected 100,000-cell injections were rechallenged with 
500,000 YUMMER1.7-H2B-GFP cells. Tissue samples containing GFP-positive tumor 
cells were harvested under a fluorescent microscope at 1 hour, 6 hours, 1 day, 2 days, 3 
days, 4 days, 7 days, and 9 days following injection. Samples were formalin-fixed and 
paraffin-embedded using standard methods. Immunohistochemistry was performed with 
standard methods using a GFP antibody to identify tumor cells, an anti-mouse CD3 
antibody to identify T lymphocytes, and an anti-mouse cleaved caspase 3 antibody to 
identify apoptotic cells. Histology and immunohistochemistry were reviewed by William 
Damsky, MD, PhD and Marcus Bosenberg, MD, PhD.  
 
Results 
 The tissue damage inherent to surgery is likely to generate damage-associated 
molecular patterns that stimulate innate immune cells. This raises the question of 
whether incision-specific immune engagement would impact the anti-tumor immune 
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response. To address this, 10 wildtype C57Bl/6J mice underwent mock surgeries to their 
left flanks while 10 age-matched control mice did not. On post-operative day 14, mice in 
each group received injections of either 500,000 (5 mice per group) or 50,000 (5 mice 
per group) YUMMER1.7-H2B-GFP cells on their right flanks. As shown in the Kaplan-
Meier curves in Figure 4.1A, survival did not differ when mock surgeries were performed 
in mice that received 500,000-cell injections, and all mice reached endpoint by post-
injection day 25. Similarly, survival did not differ when mock surgeries were performed in 
mice that received 50,000-cell injections (Figure 4.1B), with 40% of mice rejecting tumor 
cells in both groups.  
 Next, we set out to determine whether post-operative rechallenges would result 
in successful memory responses. 30 wildtype C57Bl/6J mice received injections of 
500,000 YUMMER1.7-H2B-GFP cells into their right flanks, and another 16 wildtype 
mice were designated as controls. The 30 experimental mice developed palpable tumors 
by post-injection day 7, and these tumors were resected on post-injection day 12 when 
they were approximately 1 cm in maximal dimension. This timepoint was chosen to allow 
for adequate immune exposure to tumor cells (Figure 1C.10) (187) while avoiding tumor 
invasion into the underlying back fascia and musculature, which would greatly increase 
the likelihood of incomplete resection and postoperative complications. Lack of invasion 
was grossly confirmed upon observation of resected tumors confined within their tumor 
capsules (Figure 4.2C). Of the 30 surgical mice, 2 were euthanized due to intraoperative 
complications (1 pneumothorax and 1 hernia) and 1 was euthanized on post-operative 
day 3 due to wound dehiscence. Example pre- and post-operative images are shown in 
Figure 4.2A-C.  
Post-operative mice were rechallenged on post-injection day 30 (post-operative 
day 18) to minimize the impact of immune activation related to wound repair. Of the 27 
surviving mice, 20 were rechallenged with 500,000 YUMMER1.7-H2B-GFP cells and 7 
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were rechallenged with 50,000 YUMMER1.7-H2B-GFP cells. Rechallenge injections 
were administered into the left flanks to facilitate distinction between resected tumor 
regrowth and new tumor growth. Also at this time point, the 16 control mice received 
injections of either 500,000 (8 mice) or 50,000 (8 mice) YUMMER1.7-H2B-GFP cells into 
their left flanks. The cells administered to both post-operative and control mice were 
taken from the same culture plate. None of the 27 post-operative mice grew tumors 
following rechallenge while all of the control mice injected with 500,000 cells and 50% of 
the control mice injected with 50,000 cells grew tumors and reached endpoint by post-
injection day 30, as shown by the Kaplan-Meier curves in Figure 4.3. Rechallenged mice 

















Figure 4.1: Mock surgery does not affect tumor growth. A. Survival of mice injected 
with 500,000 YUMMER1.7-H2B-GFP cells with and without mock surgery. p=0.9241. B. 
Survival of mice injected with 50,000 YUMMER1.7-H2B-GFP cells with and without 
mock surgery. p=0.8268. 40% of mice rejected tumor cells regardless of mock surgery.  
 
























































Figure 4.2: Tumor resection surgery. A. Pre-operative YUMMER1.7-H2B-GFP 
melanoma tumor visible on right posterior flank. B. Surgical wound repaired with suture 
















Figure 4.3: Post-surgical rechallenges provoke an immune memory response. A. 
Survival of mice injected with 50,000 YUMMER1.7-H2B-GFP cells with and without prior 
tumor resection. p=0.0365. B. Survival of mice injected with 500,000 YUMMER1.7-H2B-











































To determine the kinetics of the anti-tumor immune memory response, we used 
16 “memory mice” that had previously rejected injections of 100,000 YUMMER1.7-H2B-
GFP cells. Injections of 500,000 YUMMER1.7-H2B-GFP cells were administered to their 
left flanks, contralateral to the sites of their previous injections. Mice were euthanized, 
and tissue containing tumor cells was resected under fluorescent microscopy at the 
following post-injection time points: 1 hour (1 mouse), 6 hours (1 mouse), 1 day (2 mice), 
2 days (2 mice), 3 days (2 mice), 4 days (2 mice), 7 days (1 mouse), and 9 days (1 
mouse). These timepoints were selected based on pilot data suggesting that tumor 
killing was occurring between 24 hours and 5 days post-injection. The remaining 4 mice 
were used as controls to verify that the tumor cells were provoking a memory response; 
none developed tumors. Immunohistochemical staining for CD3 demonstrated that T-cell 
infiltration and tumor killing peaked at 2 days post-injection and gradually diminished 






Figure 4.4: The immune memory response peaks on post-injection day 2. CD3 
staining (brown) demonstrates that T cell infiltration and tumor killing is minimal at 24 
hours post-rechallenge (A), peaks at 48 hours post-rechallenge (B), and diminishes by 9 





A successful adaptive immune response begins with an expansion phase during 
which T cells recognize MHC-bound antigen, proliferate, and clear the antigen. This 
phase is followed by a contraction phase during which most antigen-specific T cells 
undergo apoptosis, and the remaining T cells differentiate into memory cells (256). In 
contrast to such successful immune responses, however, several aberrant states of T 
cell activation and differentiation, which result in varying degrees of T cell dysfunction, 
have been described in the literature (256). Perhaps the best studied of these aberrant 
states occurs with chronic exposure to viral infections including murine lymphocytic 
choriomeningitis virus (LCMV) clone 3. In this setting, CD8+ T lymphocytes initially 
proliferate and acquire effector function as seen in successful immune responses. Over 
time, however, they sequentially lose the ability to produce IL-2, TNFα, and IFNγ (251) 
and concurrently upregulate expression of inhibitory receptors including PD-1, LAG-3, 
CD160, 2B4, TIM-3, BTLA, and CTLA-4 (257). In this “exhausted state,” T cells are able 
to maintain a semblance of control over the infection without eradicating it, a property 
thought to mitigate the potential for autoimmune toxicity that would accompany a strong 
antiviral response (258). 
To study the role of T cell exhaustion in cancer progression, Schietinger, et al. 
used a tamoxifen-inducible, autochthonous hepatocellular carcinoma model to show that 
genes associated with T cell effector function are downregulated with prolonged 
exposure to tumor antigen (259). They further showed that the capacity for functional 
restoration by antigen removal or inhibitory receptor blockade diminishes with time. 
Selective upregulation of genes encoding epigenetic modifiers occurred in concert with 
this loss of restorative capacity, suggesting that this dysfunctional genetic program 
becomes imprinted in tumor-specific T cells. Notably, several differences in gene 
expression profiles were observed between the exhausted T cells described in the 
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context of chronic viral infections and dysfunctional tumor-specific T cells. This suggests 
that although certain changes in gene expression occur with chronic exposure to 
antigens regardless of their nature, the specific flavor of T cell dysfunction that occurs is 
context-dependent.  
To explore the impact and define the characteristics of T cell dysfunction in 
melanoma progression specifically, we aimed to develop a model with which to compare 
T cell functionality in failed and successful anti-YUMMER1.7 immune responses. The 
potential for variability in anti-tumor immunity among mice, however, threatens the 
validity of conclusions drawn from experiments in which a formed tumor from one mouse 
is compared to a rejecting tumor in another. We sought to address this by comparing 
established YUMMER1.7 tumors to actively rejecting YUMMER1.7 tumors in the same 
mice by resecting established cutaneous tumors and subsequently rechallenging post-
operative mice with additional YUMMER1.7 cells to provoke an immune memory 
response. We observed no tumor growth in mice rechallenged with 50,000 or 500,000 
YUMMER1.7 cells, suggesting that rechallenges are indeed rejected by a robust 
immune memory response. We additionally showed that the resection process itself 
does not grossly impact the observed growth pattern of injected YUMMER1.7 cells.  
While the existence of a robust post-operative memory response lends support to 
our hypothesis that the tumor microenvironment plays a more significant role in tumor 
escape than does T cell dysfunction, there remains the possibility that the T cell 
populations responsible for the initial failed immune responses and the subsequent 
successful responses were distinct. In order to address this possibility, we plan to pursue 
a series of adoptive transfer experiments. Briefly, YUMMER1.7 cells expressing 
ovalbumin (OVA) will be injected into OT-I mice whose T cells are genetically modified to 
recognize an MHC-bound ovalbumin fragment (260). Tumors will be allowed to grow and 
become infiltrated with T cells, after which they will be excised. TILs will be dissociated 
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from tumors and will then be adoptively transferred into wildtype mice bearing 
YUMMER1.7-OVA tumors. Post-transfer tumor behavior will shed light on the extent of T 
cell dysfunction that occurs during an initial tumor cell challenge. In addition to adoptive 
transfer experiments, we plan to perform single cell RNA sequencing on samples from 
growing and rejecting tumors, paying particular attention to differences in expression of 
exhaustion and activation markers among the samples.  
 
Conclusion 
 In summary, we demonstrated that rechallenging mice with YUMMER1.7 tumor 
cells following complete tumor excision reliably results in a robust immune memory 
response and tumor rejection. We thus developed a novel protocol by which both failed 
and successful anti-tumor immune responses can be studied in individual mice. This 
protocol can be used in future experiments to characterize the immune infiltration 
patterns, histologic features, and gene expression profiles that distinguish regressing 
















1. Matthews Nh Fau - Li W-Q, Li Wq Fau - Qureshi AA, Qureshi Aa Fau - 
Weinstock MA, Weinstock Ma Fau - Cho E, Cho E. Epidemiology of Melanoma BTI - 
Cutaneous Melanoma: Etiology and Therapy LID - 
10.15586/codon.cutaneousmelanoma.2017 [doi]. 20180221 ISBN- 9780994438140. 
eng. 
2. Linos E, Swetter Sm Fau - Cockburn MG, Cockburn Mg Fau - Colditz GA, Colditz 
Ga Fau - Clarke CA, Clarke CA. Increasing burden of melanoma in the United States. 
(1523-1747 (Electronic)). eng. 
3. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and 
treatment in the 21st century. (0007-9235 (Print)). eng. 
4. Kosary CL, Altekruse Sf Fau - Ruhl J, Ruhl J Fau - Lee R, Lee R Fau - Dickie L, 
Dickie L. Clinical and prognostic factors for melanoma of the skin using SEER registries: 
collaborative stage data collection system, version 1 and version 2. (1097-0142 
(Electronic)). eng. 
5. Guy Gp Jr Fau - Thomas CC, Thomas Cc Fau - Thompson T, Thompson T Fau - 
Watson M, Watson M Fau - Massetti GM, Massetti Gm Fau - Richardson LC, 
Richardson LC. Vital signs: melanoma incidence and mortality trends and projections - 
United States, 1982-2030. (1545-861X (Electronic)). eng. 
6. Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the 
science on prevention and screening to reduce melanoma incidence and mortality: The 
time is now. LID - 10.3322/caac.21352 [doi]. (1542-4863 (Electronic)). eng. 
	 83	
7. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic 
disease. Dermatol Ther. 2006 Jan-Feb;19(1):19-25. PubMed PMID: 16405566. Epub 
2006/01/13. eng. 
8. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or 
Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Sep 24;373(13):1270-1. 
PubMed PMID: 26398076. Epub 2015/09/24. eng. 
9. Clark WH, Jr., Elder DE, Van Horn M. The biologic forms of malignant 
melanoma. Hum Pathol. 1986 May;17(5):443-50. PubMed PMID: 3699806. Epub 
1986/05/01. eng. 
10. Arrington JH, 3rd, Reed RJ, Ichinose H, Krementz ET. Plantar lentiginous 
melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg 
Pathol. 1977 Jun;1(2):131-43. PubMed PMID: 602975. Epub 1977/06/01. eng. 
11. Pandiani C, Beranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous 
and uveal melanoma specificities. Genes Dev. 2017 Apr 15;31(8):724-43. PubMed 
PMID: 28512236. PMCID: PMC5435887. Epub 2017/05/18. eng. 
12. Vazquez Vde L, Vicente AL, Carloni A, Berardinelli G, Soares P, Scapulatempo 
C, et al. Molecular profiling, including TERT promoter mutations, of acral lentiginous 
melanomas. Melanoma Res. 2016 Apr;26(2):93-9. PubMed PMID: 26709572. Epub 
2015/12/29. eng. 
13. Merkel EA, Gerami P. Malignant melanoma of sun-protected sites: a review of 
clinical, histological, and molecular features. Lab Invest. 2017 Jun;97(6):630-5. PubMed 
PMID: 28092366. Epub 2017/01/17. eng. 
14. Kim JY, Choi M, Jo SJ, Min HS, Cho KH. Acral lentiginous melanoma: indolent 
subtype with long radial growth phase. Am J Dermatopathol. 2014 Feb;36(2):142-7. 
PubMed PMID: 24556899. Epub 2014/02/22. eng. 
	 84	
15. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for 
patients with cutaneous melanoma in a population-based study. Cancer. 1996 Aug 
1;78(3):427-32. PubMed PMID: 8697387. Epub 1996/08/01. eng. 
16. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. 
Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 
17;353(20):2135-47. PubMed PMID: 16291983. Epub 2005/11/18. eng. 
17. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et 
al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. 
Nature. 2013 Jul 11;499(7457):214-8. PubMed PMID: 23770567. PMCID: PMC3919509. 
Epub 2013/06/19. eng. 
18. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A 
landscape of driver mutations in melanoma. Cell. 2012 Jul 20;150(2):251-63. PubMed 
PMID: 22817889. PMCID: PMC3600117. Epub 2012/07/24. eng. 
19. Harris RS. Cancer mutation signatures, DNA damage mechanisms, and potential 
clinical implications. Genome Med. 2013;5(9):87. PubMed PMID: 24073723. PMCID: 
PMC3978439. Epub 2013/10/01. eng. 
20. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an 
abundant form of oxidative DNA damage, causes G----T and A----C substitutions. J Biol 
Chem. 1992 Jan 5;267(1):166-72. PubMed PMID: 1730583. Epub 1992/01/05. eng. 
21. Network TCGA. Genomic Classification of Cutaneous Melanoma. Cell. 2015 Jun 
18;161(7):1681-96. PubMed PMID: 26091043. PMCID: PMC4580370. Epub 2015/06/20. 
eng. 
22. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of 
the BRAF gene in human cancer. Nature. 2002 Jun 27;417(6892):949-54. PubMed 
PMID: 12068308. Epub 2002/06/18. eng. 
	 85	
23. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, et al. Ras 
activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. 
Recent Prog Horm Res. 2001;56:127-55. PubMed PMID: 11237210. Epub 2001/03/10. 
eng. 
24. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. 
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat 
Genet. 2012 Sep;44(9):1006-14. PubMed PMID: 22842228. PMCID: PMC3432702. 
Epub 2012/07/31. eng. 
25. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome 
sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. 
Nat Genet. 2011 Dec 25;44(2):133-9. PubMed PMID: 22197931. Epub 2011/12/27. eng. 
26. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently 
harbor NRAS mutations but no BRAF mutations. J Invest Dermatol. 2007 
Jan;127(1):179-82. PubMed PMID: 16888631. Epub 2006/08/05. eng. 
27. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High 
frequency of BRAF mutations in nevi. Nat Genet. 2003 Jan;33(1):19-20. PubMed PMID: 
12447372. Epub 2002/11/26. eng. 
28. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, 
et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer 
Cell. 2009 Apr 7;15(4):294-303. PubMed PMID: 19345328. Epub 2009/04/07. eng. 
29. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, et al. 
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes 
to melanomagenesis. Genes Dev. 2012 May 15;26(10):1055-69. PubMed PMID: 
22549727. PMCID: PMC3360561. Epub 2012/05/03. eng. 
30. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 
2003 May 19;22(20):3113-22. PubMed PMID: 12789288. Epub 2003/06/06. eng. 
	 86	
31. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka 
T, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006 Jul 
1;66(13):6546-52. PubMed PMID: 16818626. Epub 2006/07/05. eng. 
32. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle 
MR, et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. 
PLoS One. 2012;7(8):e43369. PubMed PMID: 22912864. PMCID: PMC3422312. Epub 
2012/08/23. eng. 
33. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A 
novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008 Oct 
21;99(8):1265-8. PubMed PMID: 18813315. PMCID: PMC2570525. Epub 2008/09/25. 
eng. 
34. Halaban R. RAC1 and melanoma. Clin Ther. 2015 Mar 1;37(3):682-5. PubMed 
PMID: 25465943. PMCID: PMC4415501. Epub 2014/12/04. eng. 
35. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et 
al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 
May 9;485(7399):502-6. PubMed PMID: 22622578. PMCID: PMC3367798. Epub 
2012/05/25. eng. 
36. Bennett DC. How to make a melanoma: what do we know of the primary clonal 
events? Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38. PubMed PMID: 18353141. 
Epub 2008/03/21. eng. 
37. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways 
and therapeutic targets in melanoma. Oncotarget. 2014 Apr 15;5(7):1701-52. PubMed 
PMID: 24743024. PMCID: PMC4039128. Epub 2014/04/20. eng. 
38. Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 
2017 Jun 1;123(S11):2104-17. PubMed PMID: 28543693. Epub 2017/05/26. eng. 
	 87	
39. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent 
TERT promoter mutations in human melanoma. Science. 2013 Feb 22;339(6122):957-9. 
PubMed PMID: 23348506. PMCID: PMC4423787. Epub 2013/01/26. eng. 
40. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT 
promoter mutations in familial and sporadic melanoma. Science. 2013 Feb 
22;339(6122):959-61. PubMed PMID: 23348503. Epub 2013/01/26. eng. 
41. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, et al. Cancer. 
The transcription factor GABP selectively binds and activates the mutant TERT promoter 
in cancer. Science. 2015 May 29;348(6238):1036-9. PubMed PMID: 25977370. PMCID: 
PMC4456397. Epub 2015/05/16. eng. 
42. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. 
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in 
malignant melanoma. Nature. 2005 Jul 7;436(7047):117-22. PubMed PMID: 16001072. 
Epub 2005/07/08. eng. 
43. Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression 
and activity. Cell Mol Life Sci. 2015 Apr;72(7):1249-60. PubMed PMID: 25433395. 
PMCID: PMC4363485. Epub 2014/12/01. eng. 
44. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and 
therapeutics in the genomic era. Genes Dev. 2006 Aug 15;20(16):2149-82. PubMed 
PMID: 16912270. Epub 2006/08/17. eng. 
45. Prickett TD, Zerlanko BJ, Hill VK, Gartner JJ, Qutob N, Jiang J, et al. Somatic 
mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity 
via aberrant NMDAR complex formation. J Invest Dermatol. 2014 Sep;134(9):2390-8. 
PubMed PMID: 24739903. PMCID: PMC4134353. Epub 2014/04/18. eng. 
46. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, et al. Exon 
capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 
	 88	
in melanoma. Nat Genet. 2011 Sep 25;43(11):1119-26. PubMed PMID: 21946352. 
PMCID: PMC3376644. Epub 2011/09/29. eng. 
47. Neto A, Ceol CJ. Melanoma-associated GRM3 variants dysregulate melanosome 
trafficking and cAMP signaling. Pigment Cell Melanoma Res. 2018 Jan;31(1):115-9. 
PubMed PMID: 28646617. Epub 2017/06/25. eng. 
48. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, et al. 
MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012 
Aug;18(8):1239-47. PubMed PMID: 22820643. PMCID: PMC3744207. Epub 
2012/07/24. eng. 
49. Stefansson B, Brautigan DL. Protein phosphatase PP6 N terminal domain 
restricts G1 to S phase progression in human cancer cells. Cell Cycle. 2007 Jun 
1;6(11):1386-92. PubMed PMID: 17568194. Epub 2007/06/15. eng. 
50. Valentin-Vega YA, Wang YD, Parker M, Patmore DM, Kanagaraj A, Moore J, et 
al. Cancer-associated DDX3X mutations drive stress granule assembly and impair 
global translation. Sci Rep. 2016 May 16;6:25996. PubMed PMID: 27180681. PMCID: 
PMC4867597. Epub 2016/05/18. eng. 
51. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald 
JE, et al. A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget. 2014 May 
30;5(10):2912-7. PubMed PMID: 24913145. PMCID: PMC4102779. Epub 2014/06/11. 
eng. 
52. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and 
losses in primary cutaneous melanomas detected by comparative genomic hybridization. 
Cancer Res. 1998 May 15;58(10):2170-5. PubMed PMID: 9605762. Epub 1998/05/30. 
eng. 
	 89	
53. van den Bosch T, Kilic E, Paridaens D, de Klein A. Genetics of uveal melanoma 
and cutaneous melanoma: two of a kind? Dermatol Res Pract. 2010;2010:360136. 
PubMed PMID: 20631901. PMCID: PMC2902045. Epub 2010/07/16. eng. 
54. James AWM, Chang LB, Shrestha S, Cochran AM, Binder SM, Tirado CAP. 
Cytogenetics of melanoma: a review. J Assoc Genet Technol. 2014;40(4):209-18. 
PubMed PMID: 26030295. Epub 2014/01/01. eng. 
55. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. 
Whole-genome landscapes of major melanoma subtypes. Nature. 2017 May 
11;545(7653):175-80. PubMed PMID: 28467829. Epub 2017/05/04. eng. 
56. Bastian BC, Kashani-Sabet M, Hamm H, Godfrey T, Moore DH, 2nd, Brocker EB, 
et al. Gene amplifications characterize acral melanoma and permit the detection of 
occult tumor cells in the surrounding skin. Cancer Res. 2000 Apr 1;60(7):1968-73. 
PubMed PMID: 10766187. Epub 2000/04/15. eng. 
57. Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D, et al. The 
mutational burden of acral melanoma revealed by whole-genome sequencing and 
comparative analysis. Pigment Cell Melanoma Res. 2014 Sep;27(5):835-8. PubMed 
PMID: 24913711. Epub 2014/06/11. eng. 
58. Kong Y, Sheng X, Wu X, Yan J, Ma M, Yu J, et al. Frequent Genetic Aberrations 
in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in 
Targeted Therapy. Clin Cancer Res. 2017 Nov 15;23(22):6946-57. PubMed PMID: 
28830923. Epub 2017/08/24. eng. 
59. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct 
subtypes of melanoma. J Clin Oncol. 2006 Sep 10;24(26):4340-6. PubMed PMID: 
16908931. Epub 2006/08/16. eng. 
	 90	
60. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular 
medicine and targeted therapeutics. Biochem Pharmacol. 2010 Sep 1;80(5):568-74. 
PubMed PMID: 20457136. PMCID: PMC3935736. Epub 2010/05/12. eng. 
61. Dumaz N, Andre J, Sadoux A, Laugier F, Podgorniak MP, Mourah S, et al. Driver 
KIT mutations in melanoma cluster in four hotspots. Melanoma Res. 2015 Feb;25(1):88-
90. PubMed PMID: 25304235. Epub 2014/10/12. eng. 
62. Fukuda R, Hamamoto N, Uchida Y, Furuta K, Katsube T, Kazumori H, et al. 
Gastrointestinal stromal tumor with a novel mutation of KIT proto-oncogene. Intern Med. 
2001 Apr;40(4):301-3. PubMed PMID: 11334388. Epub 2001/05/04. eng. 
63. Dai J, Kong Y, Si L, Chi Z, Cui C, Sheng X, et al. Large-scale analysis of 
PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase 
inhibitors imatinib and crenolanib. Clin Cancer Res. 2013 Dec 15;19(24):6935-42. 
PubMed PMID: 24132921. Epub 2013/10/18. eng. 
64. Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): a target 
for anticancer therapeutics. Drug Resist Updat. 2005 Feb-Apr;8(1-2):75-83. PubMed 
PMID: 15939344. Epub 2005/06/09. eng. 
65. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for 
understanding melanoma. J Investig Dermatol Symp Proc. 2005 Nov;10(2):153-63. 
PubMed PMID: 16358819. Epub 2005/12/20. eng. 
66. Yan J, Wu X, Yu J, Yu H, Xu T, Brown KM, et al. Analysis of NRAS gain in 657 
patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. Eur J Cancer. 
2018 Jan;89:90-101. PubMed PMID: 29245078. Epub 2017/12/16. eng. 
67. Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, et al. 
Whole genome sequencing of matched primary and metastatic acral melanomas. 
Genome Res. 2012 Feb;22(2):196-207. PubMed PMID: 22183965. PMCID: 
PMC3266028. Epub 2011/12/21. eng. 
	 91	
68. Diaz A, Puig-Butille JA, Valera A, Munoz C, Costa D, Garcia-Herrera A, et al. 
TERT and AURKA gene copy number gains enhance the detection of acral lentiginous 
melanomas by fluorescence in situ hybridization. J Mol Diagn. 2014 Mar;16(2):198-206. 
PubMed PMID: 24374110. Epub 2014/01/01. eng. 
69. Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT, Liang CW. TERT promoter 
mutation is uncommon in acral lentiginous melanoma. J Cutan Pathol. 2014 
Jun;41(6):504-8. PubMed PMID: 24588324. Epub 2014/03/05. eng. 
70. Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. 
Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 
2013;6(7):1230-44. PubMed PMID: 23826405. PMCID: PMC3693189. Epub 2013/07/05. 
eng. 
71. Helgadottir H, Hoiom V. The genetics of uveal melanoma: current insights. Appl 
Clin Genet. 2016;9:147-55. PubMed PMID: 27660484. PMCID: PMC5019476. Epub 
2016/09/24. eng. 
72. Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, et al. 
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes 
similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013 Jun 
15;19(12):3143-52. PubMed PMID: 23633454. Epub 2013/05/02. eng. 
73. Testa U, Castelli G, Pelosi E. Melanoma: Genetic Abnormalities, Tumor 
Progression, Clonal Evolution and Tumor Initiating Cells. Med Sci (Basel). 2017 Nov 
20;5(4). PubMed PMID: 29156643. PMCID: PMC5753657. Epub 2017/11/22. eng. 
74. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, 
et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 
2009 Jan 29;457(7229):599-602. PubMed PMID: 19078957. PMCID: PMC2696133. 
Epub 2008/12/17. eng. 
	 92	
75. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner 
T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010 Dec 
2;363(23):2191-9. PubMed PMID: 21083380. PMCID: PMC3107972. Epub 2010/11/19. 
eng. 
76. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues 
M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene 
through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014 Jun 
16;25(6):831-45. PubMed PMID: 24882515. PMCID: PMC4074519. Epub 2014/06/03. 
eng. 
77. Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. 
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal 
melanoma. Nat Genet. 2016 Jun;48(6):675-80. PubMed PMID: 27089179. PMCID: 
PMC5032652. Epub 2016/04/19. eng. 
78. Mong S, Miller J, Wu HL, Crooke ST. Leukotriene D4 receptor-mediated 
hydrolysis of phosphoinositide and mobilization of calcium in sheep tracheal smooth 
muscle cells. J Pharmacol Exp Ther. 1988 Feb;244(2):508-15. PubMed PMID: 2831343. 
Epub 1988/02/01. eng. 
79. Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, et al. 
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. 
Oncotarget. 2016 Jan 26;7(4):4624-31. PubMed PMID: 26683228. PMCID: 
PMC4826231. Epub 2015/12/20. eng. 
80. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. 
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010 Dec 
3;330(6009):1410-3. PubMed PMID: 21051595. PMCID: PMC3087380. Epub 
2010/11/06. eng. 
	 93	
81. Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, et al. 
Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One. 
2017;12(6):e0178189. PubMed PMID: 28594900. PMCID: PMC5464544. Epub 
2017/06/09. eng. 
82. Ismail IH, Davidson R, Gagne JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline 
mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 
2014 Aug 15;74(16):4282-94. PubMed PMID: 24894717. Epub 2014/06/05. eng. 
83. Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. 
BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC 
Cancer. 2013 Aug 5;13:371. PubMed PMID: 23915344. PMCID: PMC3846494. Epub 
2013/08/07. eng. 
84. Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, et al. Germline 
mutation of Bap1 accelerates development of asbestos-induced malignant 
mesothelioma. Cancer Res. 2014 Aug 15;74(16):4388-97. PubMed PMID: 24928783. 
PMCID: PMC4165574. Epub 2014/06/15. eng. 
85. Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. 
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal 
melanoma with disomy 3. Nat Genet. 2013 Aug;45(8):933-6. PubMed PMID: 23793026. 
PMCID: PMC4307600. Epub 2013/06/26. eng. 
86. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. 
Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-
gene prognostic assay in uveal melanoma. Ophthalmology. 2012 Aug;119(8):1596-603. 
PubMed PMID: 22521086. PMCID: PMC3404209. Epub 2012/04/24. eng. 
87. Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, et al. 
Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat 
	 94	
Commun. 2018 Jan 9;9(1):116. PubMed PMID: 29317634. PMCID: PMC5760704. Epub 
2018/01/11. eng. 
88. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. 
Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin 
Cancer Res. 2008 Feb 15;14(4):951-6. PubMed PMID: 18281525. Epub 2008/02/19. 
eng. 
89. van den Bosch T, van Beek JG, Vaarwater J, Verdijk RM, Naus NC, Paridaens 
D, et al. Higher percentage of FISH-determined monosomy 3 and 8q amplification in 
uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci. 2012 
May 14;53(6):2668-74. PubMed PMID: 22427574. Epub 2012/03/20. eng. 
90. de Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression 
genes. Cancer Lett. 2005 Dec 18;230(2):153-86. PubMed PMID: 16297704. Epub 
2005/11/22. eng. 
91. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, 
et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994 Sep;8(1):15-21. 
PubMed PMID: 7987387. Epub 1994/09/01. eng. 
92. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline 
mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 
1996 Jan;12(1):97-9. PubMed PMID: 8528263. Epub 1996/01/01. eng. 
93. Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J. Lifetime risks of 
common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004 Mar 
3;96(5):357-63. PubMed PMID: 14996857. Epub 2004/03/05. eng. 
94. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline 
mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011 Aug 
28;43(10):1018-21. PubMed PMID: 21874003. PMCID: PMC3328403. Epub 2011/08/30. 
eng. 
	 95	
95. Lin M, Zhang L, Hildebrandt MAT, Huang M, Wu X, Ye Y. Common, germline 
genetic variations in the novel tumor suppressor BAP1 and risk of developing different 
types of cancer. Oncotarget. 2017 Sep 26;8(43):74936-46. PubMed PMID: 29088836. 
PMCID: PMC5650391. Epub 2017/11/02. eng. 
96. Aoude LG, Wadt KA, Pritchard AL, Hayward NK. Genetics of familial melanoma: 
20 years after CDKN2A. Pigment Cell Melanoma Res. 2015 Mar;28(2):148-60. PubMed 
PMID: 25431349. Epub 2014/11/29. eng. 
97. Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, et al. Frequent 
mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res. 2009 
Aug;22(4):435-44. PubMed PMID: 19422606. PMCID: PMC2728363. Epub 2009/05/09. 
eng. 
98. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A 
SUMOylation-defective MITF germline mutation predisposes to melanoma and renal 
carcinoma. Nature. 2011 Oct 19;480(7375):94-8. PubMed PMID: 22012259. Epub 
2011/10/21. eng. 
99. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, et al. 
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. 
Nature. 2011 Nov 13;480(7375):99-103. PubMed PMID: 22080950. PMCID: 
PMC3266855. Epub 2011/11/15. eng. 
100. Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP, et al. 
Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of 
melanocytes. J Cell Biol. 1998 Aug 10;142(3):827-35. PubMed PMID: 9700169. PMCID: 
PMC2148160. Epub 1998/08/12. eng. 
101. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, et al. MC1R is a 
potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013 Aug 
	 96	
22;51(4):409-22. PubMed PMID: 23973372. PMCID: PMC3792490. Epub 2013/08/27. 
eng. 
102. Vajdic C, Kricker A, Duffy DL, Aitken JF, Stark M, ter Huurne JA, et al. Ocular 
melanoma is not associated with CDKN2A or MC1R variants--a population-based study. 
Melanoma Res. 2003 Aug;13(4):409-13. PubMed PMID: 12883368. Epub 2003/07/29. 
eng. 
103. van Zeijl MC, van den Eertwegh AJ, Haanen JB, Wouters MW. (Neo)adjuvant 
systemic therapy for melanoma. Eur J Surg Oncol. 2017 Mar;43(3):534-43. PubMed 
PMID: 27453302. Epub 2016/07/28. eng. 
104. Kim C, Lee CW, Kovacic L, Shah A, Klasa R, Savage KJ. Long-term survival in 
patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist. 
2010;15(7):765-71. PubMed PMID: 20538743. PMCID: PMC3228011. Epub 2010/06/12. 
eng. 
105. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. 
Randomized phase III study of temozolomide versus dacarbazine in the treatment of 
patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 
Jan;18(1):158-66. PubMed PMID: 10623706. Epub 2000/01/07. eng. 
106. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 
2003 May 19;22(20):3138-51. PubMed PMID: 12789290. Epub 2003/06/06. eng. 
107. Wilson MA, Schuchter LM. Chemotherapy for Melanoma. Cancer Treat Res. 
2016;167:209-29. PubMed PMID: 26601864. Epub 2015/11/26. eng. 
108. Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs. 2013 
Aug;73(12):1367-76. PubMed PMID: 23881668. Epub 2013/07/25. eng. 
109. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. 
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J 
	 97	
Med. 2011 Jun 30;364(26):2507-16. PubMed PMID: 21639808. PMCID: PMC3549296. 
Epub 2011/06/07. eng. 
110. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF 
inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. 
Clin Cancer Res. 2014 Apr 1;20(7):1965-77. PubMed PMID: 24463458. Epub 
2014/01/28. eng. 
111. Wright CJ, McCormack PL. Trametinib: first global approval. Drugs. 2013 
Jul;73(11):1245-54. PubMed PMID: 23846731. Epub 2013/07/13. eng. 
112. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved 
survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 
12;367(2):107-14. PubMed PMID: 22663011. Epub 2012/06/06. eng. 
113. Niezgoda A, Niezgoda P, Czajkowski R. Novel Approaches to Treatment of 
Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res 
Int. 2015;2015:851387. PubMed PMID: 26171394. PMCID: PMC4478296. Epub 
2015/07/15. eng. 
114. Boespflug A, Thomas L. Cobimetinib and vemurafenib for the treatment of 
melanoma. Expert Opin Pharmacother. 2016;17(7):1005-11. PubMed PMID: 26999478. 
Epub 2016/03/22. eng. 
115. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. BRAF, MEK and KIT 
inhibitors for melanoma: adverse events and their management. Chin Clin Oncol. 2014 
Sep;3(3):29. PubMed PMID: 25841455. Epub 2015/04/07. eng. 
116. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, 
et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on 
mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 
10;31(26):3182-90. PubMed PMID: 23775962. PMCID: PMC4878082. Epub 2013/06/19. 
eng. 
	 98	
117. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. 
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 
20;26(12):2046-51. PubMed PMID: 18421059. Epub 2008/04/19. eng. 
118. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-
arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit 
mutation or amplification. J Clin Oncol. 2011 Jul 20;29(21):2904-9. PubMed PMID: 
21690468. Epub 2011/06/22. eng. 
119. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of 
vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in 
vivo. Nature. 1993 Apr 29;362(6423):841-4. PubMed PMID: 7683111. Epub 1993/04/29. 
eng. 
120. Li X, Wu D, Shen J, Zhou M, Lu Y. Rapamycin induces autophagy in the 
melanoma cell line M14 via regulation of the expression levels of Bcl-2 and Bax. Oncol 
Lett. 2013 Jan;5(1):167-72. PubMed PMID: 23255914. PMCID: PMC3525347. Epub 
2012/12/21. eng. 
121. O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. 
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. PubMed PMID: 27030077. Epub 
2016/04/01. eng. 
122. Domingues B, Lopes JM, Soares P, Populo H. Melanoma treatment in review. 
Immunotargets Ther. 2018;7:35-49. PubMed PMID: 29922629. PMCID: PMC5995433. 
Epub 2018/06/21. eng. 
123. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases 
from melanoma: review of the literature. Melanoma Res. 2009 Oct;19(5):275-82. 
PubMed PMID: 19633580. Epub 2009/07/28. eng. 
124. Jakob JA, Bassett RL, Jr., Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. 
NRAS mutation status is an independent prognostic factor in metastatic melanoma. 
	 99	
Cancer. 2012 Aug 15;118(16):4014-23. PubMed PMID: 22180178. PMCID: 
PMC3310961. Epub 2011/12/20. eng. 
125. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. 
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary 
cutaneous melanoma. Cancer. 1996 Apr 1;77(7):1303-10. PubMed PMID: 8608507. 
Epub 1996/04/01. eng. 
126. Oble DA, Loewe R, Yu P, Mihm MC, Jr. Focus on TILs: prognostic significance of 
tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009 Apr 2;9:3. 
PubMed PMID: 19338264. PMCID: PMC2935762. Epub 2009/04/03. eng. 
127. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, et al. The 
tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes 
on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489-95. PubMed PMID: 
8340755. PMCID: PMC2191123. Epub 1993/08/01. eng. 
128. Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, et al. 
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted 
Melan-A/MART-1 antigenic peptide in melanoma. J Immunol. 1997 Sep 1;159(5):2366-
74. PubMed PMID: 9278327. Epub 1997/09/01. eng. 
129. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, 
et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived 
tumor-infiltrating lymphocytes. J Exp Med. 1994 Mar 1;179(3):1005-9. PubMed PMID: 
8113668. PMCID: PMC2191413. Epub 1994/03/01. eng. 
130. Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, et 
al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human 
melanoma. J Immunol. 1999 Jun 1;162(11):6849-54. PubMed PMID: 10352307. Epub 
1999/06/03. eng. 
	 100	
131. Sanlorenzo M, Vujic I, Carnevale-Schianca F, Quaglino P, Gammaitoni L, Fierro 
MT, et al. Role of interferon in melanoma: old hopes and new perspectives. Expert Opin 
Biol Ther. 2017 Apr;17(4):475-83. PubMed PMID: 28274138. Epub 2017/03/10. eng. 
132. Roh MR, Zheng Z, Kim HS, Jeung HC, Rha SY, Chung KY. Difference of 
interferon-alpha and interferon-beta on melanoma growth and lymph node metastasis in 
mice. Melanoma Res. 2013 Apr;23(2):114-24. PubMed PMID: 23358428. Epub 
2013/01/30. eng. 
133. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et 
al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival 
compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III 
melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 
1;19(9):2370-80. PubMed PMID: 11331315. Epub 2001/05/02. eng. 
134. Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN, et al. 
Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient 
data meta-analysis. Eur J Cancer. 2017 Sep;82:171-83. PubMed PMID: 28692949. 
Epub 2017/07/12. eng. 
135. Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, et al. 
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-
III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b 
(IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eur J 
Cancer. 2016 Mar;55:111-21. PubMed PMID: 26790144. Epub 2016/01/21. eng. 
136. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, et al. 
Modulation of signal transducers and activators of transcription 1 and 3 signaling in 
melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 1;13(5):1523-31. 
PubMed PMID: 17332298. Epub 2007/03/03. eng. 
	 101	
137. Hofmann MA, Kiecker F, Kuchler I, Kors C, Trefzer U. Serum TNF-alpha, B2M 
and sIL-2R levels are biological correlates of outcome in adjuvant IFN-alpha2b treatment 
of patients with melanoma. J Cancer Res Clin Oncol. 2011 Mar;137(3):455-62. PubMed 
PMID: 20454974. Epub 2010/05/11. eng. 
138. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating 
lymphocytes in metastatic malignant melanoma and response to interferon alpha 
treatment. Br J Cancer. 1996 Sep;74(5):670-6. PubMed PMID: 8845294. PMCID: 
PMC2074699. Epub 1996/09/01. eng. 
139. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. 
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected 
stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 
2008 Jul 12;372(9633):117-26. PubMed PMID: 18620949. Epub 2008/07/16. eng. 
140. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug 
Discov. 2003 Mar;2(3):214-21. PubMed PMID: 12612647. Epub 2003/03/04. eng. 
141. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. 
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy 
with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J 
Clin Oncol. 2012 Nov 1;30(31):3810-8. PubMed PMID: 23008300. Epub 2012/09/26. 
eng. 
142. Grob JJ, Jouary T, Dreno B, Asselineau J, Gutzmer R, Hauschild A, et al. 
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose 
interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an 
open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) 
study. Eur J Cancer. 2013 Jan;49(1):166-74. PubMed PMID: 22975216. Epub 
2012/09/15. eng. 
	 102	
143. Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, et al. High 
frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer 
Med. 2017 Nov;6(11):2576-85. PubMed PMID: 28994212. PMCID: PMC5673911. Epub 
2017/10/11. eng. 
144. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, et al. 
Safety and efficacy of combination immunotherapy with interferon alfa-2b and 
tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20;30(3):322-
8. PubMed PMID: 22184371. PMCID: PMC3422533. Epub 2011/12/21. eng. 
145. Haanen JB. Immunotherapy of melanoma. EJC Suppl. 2013 Sep;11(2):97-105. 
PubMed PMID: 26217118. PMCID: PMC4041176. Epub 2013/09/01. eng. 
146. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete 
responses in patients with metastatic cancer treated with high-dose interleukin-2: 
identification of the antigens mediating response. Ann Surg. 1998 Sep;228(3):307-19. 
PubMed PMID: 9742914. PMCID: PMC1191483. Epub 1998/09/22. eng. 
147. Bright R, Coventry BJ, Eardley-Harris N, Briggs N. Clinical Response Rates 
From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A 
Meta-Analysis of 3312 Patients. J Immunother. 2017 Jan;40(1):21-30. PubMed PMID: 
27875387. Epub 2016/11/23. eng. 
148. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J 
Immunol. 2014 Jun 15;192(12):5451-8. PubMed PMID: 24907378. Epub 2014/06/08. 
eng. 
149. Wang Z, Zheng Q, Zhang H, Bronson RT, Madsen JC, Sachs DH, et al. Ontak-
like human IL-2 fusion toxin. J Immunol Methods. 2017 Sep;448:51-8. PubMed PMID: 
28551309. PMCID: PMC5576150. Epub 2017/05/30. eng. 
	 103	
150. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in 
melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012 
Jan;13(1):e32-42. PubMed PMID: 22225723. Epub 2012/01/10. eng. 
151. Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, et al. Phase II 
trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with 
unresectable stage IV melanoma. BMC Cancer. 2011 Dec 13;11:515. PubMed PMID: 
22165955. PMCID: PMC3293785. Epub 2011/12/15. eng. 
152. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a 
fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to 
eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005 Nov-
Dec;28(6):582-92. PubMed PMID: 16224276. PMCID: PMC1533764. Epub 2005/10/15. 
eng. 
153. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses 
to antigen. Annu Rev Immunol. 1993;11:191-212. PubMed PMID: 8386518. Epub 
1993/01/01. eng. 
154. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune 
modulation in cancer with antibodies. Annu Rev Med. 2014;65:185-202. PubMed PMID: 
24188664. Epub 2013/11/06. eng. 
155. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW. 
Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with 
CTLA-4. Science. 1996 May 24;272(5265):1170-3. PubMed PMID: 8638161. Epub 
1996/05/24. eng. 
156. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 
ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell 
responses. Immunity. 2007 Jul;27(1):111-22. PubMed PMID: 17629517. PMCID: 
PMC2707944. Epub 2007/07/17. eng. 
	 104	
157. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 
associate with immunoreceptor tyrosine-based switch motif of programmed death 1 
upon primary human T cell stimulation, but only receptor ligation prevents T cell 
activation. J Immunol. 2004 Jul 15;173(2):945-54. PubMed PMID: 15240681. Epub 
2004/07/09. eng. 
158. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with 
PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for 
tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr;54(4):307-14. PubMed 
PMID: 15599732. Epub 2004/12/16. eng. 
159. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition 
and application to cancer therapy. Immunol Rev. 2008 Aug;224:141-65. PubMed PMID: 
18759925. Epub 2008/09/02. eng. 
160. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. 
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated 
antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 
2003 Jul 8;100(14):8372-7. PubMed PMID: 12826605. PMCID: PMC166236. Epub 
2003/06/27. eng. 
161. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. 
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 
2010 Aug 19;363(8):711-23. PubMed PMID: 20525992. PMCID: PMC3549297. Epub 
2010/06/08. eng. 
162. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. 
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J 
Med. 2011 Jun 30;364(26):2517-26. PubMed PMID: 21639810. Epub 2011/06/07. eng. 
163. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four-
year survival rates for patients with metastatic melanoma who received ipilimumab in 
	 105	
phase II clinical trials. Ann Oncol. 2013 Aug;24(8):2174-80. PubMed PMID: 23666915. 
PMCID: PMC4081656. Epub 2013/05/15. eng. 
164. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III 
randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy 
in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22. PubMed 
PMID: 23295794. PMCID: PMC4878048. Epub 2013/01/09. eng. 
165. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. 
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid 
tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin 
Oncol. 2010 Jul 1;28(19):3167-75. PubMed PMID: 20516446. PMCID: PMC4834717. 
Epub 2010/06/03. eng. 
166. Specenier P. Nivolumab in melanoma. Expert Rev Anticancer Ther. 2016 
Dec;16(12):1247-61. PubMed PMID: 27776441. Epub 2016/10/26. eng. 
167. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. 
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 
25;372(26):2521-32. PubMed PMID: 25891173. Epub 2015/04/22. eng. 
168. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety 
and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 
2012 Jun 28;366(26):2455-65. PubMed PMID: 22658128. PMCID: 3563263. 
169. Khan U, Rizvi H, Sano D, Chiu J, Hadid T. Nivolumab induced myxedema crisis. 
J Immunother Cancer. 2017;5:13. PubMed PMID: 28239466. PMCID: 5319087. 
170. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. 
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced 
Melanoma. J Clin Oncol. 2017 Mar;35(7):785-92. PubMed PMID: 28068177. 
171. Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, et al. 
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor 
	 106	
therapy. J Immunother Cancer. 2017;5:8. PubMed PMID: 28239462. PMCID: 
PMC5319013. Epub 2017/02/28. eng. 
172. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. 
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting 
chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin 
Oncol. 2005 Apr 1;23(10):2346-57. PubMed PMID: 15800326. PMCID: PMC1475951. 
Epub 2005/04/01. eng. 
173. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. 
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive 
myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008 Nov 
10;26(32):5233-9. PubMed PMID: 18809613. PMCID: PMC2652090. Epub 2008/09/24. 
eng. 
174. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et 
al. Clinical responses in a phase II study using adoptive transfer of short-term cultured 
tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010 
May 1;16(9):2646-55. PubMed PMID: 20406835. Epub 2010/04/22. eng. 
175. Zhang E, Xu H. A new insight in chimeric antigen receptor-engineered T cells for 
cancer immunotherapy. J Hematol Oncol. 2017 Jan 3;10(1):1. PubMed PMID: 
28049484. PMCID: PMC5210295. Epub 2017/01/05. eng. 
176. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin 
Oncol. 2016 Jun;13(6):370-83. PubMed PMID: 27000958. PMCID: PMC5529102. Epub 
2016/03/24. eng. 
177. Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy 
in melanoma: Recent advances and future directions. Eur J Surg Oncol. 2017 
Mar;43(3):604-11. PubMed PMID: 27769635. Epub 2016/10/23. eng. 
	 107	
178. Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma 
immunotherapy. Oncoimmunology. 2016;5(1):e1115641. PubMed PMID: 26942095. 
PMCID: PMC4760283. Epub 2016/03/05. eng. 
179. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, et al. 
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells 
presenting epitopes derived from the melanoma-associated antigens MART-1 and 
gp100. J Immunother. 2000 Jul-Aug;23(4):487-98. PubMed PMID: 10916759. Epub 
2000/08/05. eng. 
180. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman 
J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N 
Engl J Med. 2011 Jun 2;364(22):2119-27. PubMed PMID: 21631324. PMCID: 
PMC3517182. Epub 2011/06/03. eng. 
181. Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. The YUMM lines: a 
series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment 
Cell Melanoma Res. 2016 Sep;29(5):590-7. PubMed PMID: 27287723. PMCID: 
PMC5331933. Epub 2016/06/12. eng. 
182. Becker JC, Houben R, Schrama D, Voigt H, Ugurel S, Reisfeld RA. Mouse 
models for melanoma: a personal perspective. Exp Dermatol. 2010 Feb;19(2):157-64. 
PubMed PMID: 19849715. Epub 2009/10/24. eng. 
183. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr., et 
al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 
2009 May;41(5):544-52. PubMed PMID: 19282848. PMCID: PMC2705918. Epub 
2009/03/14. eng. 
184. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. 
Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546-58. PubMed PMID: 
23539594. PMCID: PMC3749880. Epub 2013/03/30. eng. 
	 108	
185. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. 
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 
2014 Dec 4;371(23):2189-99. PubMed PMID: 25409260. PMCID: PMC4315319. Epub 
2014/11/20. eng. 
186. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. 
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 
2015 Oct 9;350(6257):207-11. PubMed PMID: 26359337. PMCID: PMC5054517. Epub 
2015/09/12. eng. 
187. Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, et al. UV-induced 
somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse 
melanoma model. Pigment Cell Melanoma Res. 2017 Jul;30(4):428-35. PubMed PMID: 
28379630. PMCID: PMC5820096. Epub 2017/04/06. eng. 
188. Utzschneider DT, Alfei F, Roelli P, Barras D, Chennupati V, Darbre S, et al. High 
antigen levels induce an exhausted phenotype in a chronic infection without impairing T 
cell expansion and survival. J Exp Med. 2016 Aug 22;213(9):1819-34. PubMed PMID: 
27455951. PMCID: PMC4995073. Epub 2016/07/28. eng. 
189. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. 
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 
25;372(26):2521-32. PubMed PMID: 25891173. 
190. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. 
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed 
after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, 
phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-84. PubMed PMID: 25795410. 
191. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. 
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung 
	 109	
Cancer. J Clin Oncol. 2016 Sep 1;34(25):2980-7. PubMed PMID: 27354485. PMCID: 
5569692. 
192. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. 
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. 
N Engl J Med. 2016 Nov 10;375(19):1823-33. PubMed PMID: 27718847. 
193. Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, et 
al. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin 
Cancer Res. 2016 Nov 15;22(22):5461-71. PubMed PMID: 27169994. PMCID: 5106340. 
194. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. 
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite 
instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 
study. Lancet Oncol. 2017 Sep;18(9):1182-91. PubMed PMID: 28734759. 
195. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-
1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 
2015 Jan 22;372(4):311-9. PubMed PMID: 25482239. PMCID: 4348009. 
196. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. 
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J 
Med. 2017 Mar 16;376(11):1015-26. PubMed PMID: 28212060. PMCID: 5635424. 
197. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. 
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a 
multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-
85. PubMed PMID: 27592805. PMCID: 5587154. 
198. Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in Urothelial Cancer: 
Recent Results and Future Perspectives. Drugs. 2017 Jul;77(10):1077-89. PubMed 
PMID: 28493171. 
	 110	
199. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. 
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J 
Med. 2017 Nov 16;377(20):1919-29. PubMed PMID: 28885881. 
200. Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT, et al. 
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor 
Treatment for Metastatic Cancer. JAMA Neurol. 2016 Aug 1;73(8):928-33. PubMed 
PMID: 27271951. 
201. Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, et al. Rituximab for 
nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann 
Oncol. 2017 Sep 1;28(9):2318-9. PubMed PMID: 28911080. 
202. Khan U, Ali F, Khurram MS, Zaka A, Hadid T. Immunotherapy-associated 
autoimmune hemolytic anemia. J Immunother Cancer. 2017;5:15. PubMed PMID: 
28239468. PMCID: 5319184. 
203. Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab Treatment 
of Nivolumab-Induced Bullous Pemphigoid. JAMA Dermatol. 2017 Jun 1;153(6):603-5. 
PubMed PMID: 28355425. 
204. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. 
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects 
on Survival and Time to Treatment Failure in Patients With Melanoma Treated With 
Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015 Oct 
1;33(28):3193-8. PubMed PMID: 26282644. PMCID: 5087335 online at www.jco.org. 
Author contributions are found at the end of this article. 
205. Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L. Ipilimumab induced 
digital vasculitis. J Immunother Cancer. 2018 Feb 12;6(1):12. PubMed PMID: 29433584. 
PMCID: 5809839. 
	 111	
206. Zippelius A, Schreiner J, Herzig P, Muller P. Induced PD-L1 expression mediates 
acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015 
Mar;3(3):236-44. PubMed PMID: 25623164. 
207. Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, et al. 
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma 
Patients Treated on ECOG-ACRIN E2805. Clin Cancer Res. 2018 Jan 1;24(1):217-23. 
PubMed PMID: 29066509. 
208. Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, et al. PD-L1 
Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients 
Treated with Immune Checkpoint Inhibitors. Clin Cancer Res. 2017 Aug 1;23(15):4270-
9. PubMed PMID: 28223273. PMCID: 5540774. 
209. Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, et al. 
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal 
cell carcinoma specimens. Oncotarget. 2015 Sep 22;6(28):24990-5002. PubMed PMID: 
26317902. PMCID: 4694809. 
210. Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. 
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic 
Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res. 2015 Jul 
1;21(13):3052-60. PubMed PMID: 25788491. PMCID: 4490112. 
211. Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, et al. Prolonged 
effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus 
erythematosus. Arthritis Rheum. 2010 Aug;62(8):2443-57. PubMed PMID: 20506300. 
PMCID: 2920998. 
212. Ahmed KA, Wang L, Munegowda MA, Mulligan SJ, Gordon JR, Griebel P, et al. 
Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via 
	 112	
pMHC-I targeting and CD40L signaling. J Leukoc Biol. 2012 Aug;92(2):289-300. 
PubMed PMID: 22544940. 
213. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, et al. Active vaccination with 
Dickkopf-1 induces protective and therapeutic anti-tumor immunity in murine multiple 
myeloma. Blood. 2012 Jan 5;119(1):161-9. PubMed PMID: 22049519. PMCID: 3251227. 
214. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted 
disruption of the membrane exon of the immunoglobulin mu chain gene. Nature. 1991 
Apr 4;350(6317):423-6. PubMed PMID: 1901381. 
215. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated 
immune responses in tumor models and cancer patients. Oncoimmunology. 2013 Jul 
1;2(7):e25443. PubMed PMID: 24073382. PMCID: 3782133. 
216. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, et 
al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic 
chemotherapy. Nature. 2015 May 7;521(7550):94-8. PubMed PMID: 25924065. PMCID: 
4501632. 
217. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. 
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit 
in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011 
Oct 4;108(40):16723-8. PubMed PMID: 21933959. PMCID: 3189057. 
218. Gunderson AJ, Coussens LM. B cells and their mediators as targets for therapy 
in solid tumors. Exp Cell Res. 2013 Jul 1;319(11):1644-9. PubMed PMID: 23499742. 
PMCID: 3743954. 
219. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin 
Immunol. 2007 Apr;19(2):209-16. PubMed PMID: 17276050. 
220. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, et al. 
B cells regulate macrophage phenotype and response to chemotherapy in squamous 
	 113	
carcinomas. Cancer Cell. 2014 Jun 16;25(6):809-21. PubMed PMID: 24909985. PMCID: 
4063283. 
221. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. 
CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and 
together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer 
Res. 2012 Jun 15;18(12):3281-92. PubMed PMID: 22553348. 
222. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. 
Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 
2016 Nov 3;375(18):1749-55. PubMed PMID: 27806233. PMCID: 5247797. 
223. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, 
Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell 
function. N Engl J Med. 2009 Nov 26;361(22):2143-52. PubMed PMID: 19940299. 
224. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. 
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune 
Disorders. JAMA Oncol. 2016 Feb;2(2):234-40. PubMed PMID: 26633184. 
225. Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, 
et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for 
Multiple Sclerosis. JAMA Neurol. 2018 Jan 8. PubMed PMID: 29309484. 
226. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: 
time for reassessment. F1000Prime Rep. 2014;6:13. PubMed PMID: 24669294. PMCID: 
PMC3944738. Epub 2014/03/29. eng. 
227. Pollard JW. Tumour-educated macrophages promote tumour progression and 
metastasis. Nat Rev Cancer. 2004 Jan;4(1):71-8. PubMed PMID: 14708027. Epub 
2004/01/07. eng. 
228. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression 
identifies a novel suppressive macrophage population in human ovarian carcinoma. J 
	 114	
Exp Med. 2006 Apr 17;203(4):871-81. PubMed PMID: 16606666. PMCID: 
PMC2118300. Epub 2006/04/12. eng. 
229. Diaz-Valdes N, Basagoiti M, Dotor J, Aranda F, Monreal I, Riezu-Boj JI, et al. 
Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in 
melanoma enhances tumor infiltration and immunosuppression. Cancer Res. 2011 Feb 
1;71(3):812-21. PubMed PMID: 21159663. Epub 2010/12/17. eng. 
230. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-
1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 
Nov 27;515(7528):568-71. PubMed PMID: 25428505. PMCID: PMC4246418. Epub 
2014/11/28. eng. 
231. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, 
homeostasis and disease. Nature. 2013 Apr 25;496(7446):445-55. PubMed PMID: 
23619691. PMCID: PMC3725458. Epub 2013/04/27. eng. 
232. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. 
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves 
immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013 Feb 
1;73(3):1128-41. PubMed PMID: 23221383. PMCID: PMC3563931. Epub 2012/12/12. 
eng. 
233. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling 
blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of 
radiotherapy in prostate cancer. Cancer Res. 2013 May 1;73(9):2782-94. PubMed 
PMID: 23418320. PMCID: PMC4097014. Epub 2013/02/19. eng. 
234. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. 
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic 
tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012 Mar 
15;118(6):1649-55. PubMed PMID: 21823110. Epub 2011/08/09. eng. 
	 115	
235. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting 
tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer 
therapy. Cancer Cell. 2014 Jun 16;25(6):846-59. PubMed PMID: 24898549. Epub 
2014/06/06. eng. 
236. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. 
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in 
mice and humans. Science. 2011 Mar 25;331(6024):1612-6. PubMed PMID: 21436454. 
PMCID: PMC3406187. Epub 2011/03/26. eng. 
237. Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and 
anti-tumor activities of agonistic CD40 antibodies. Science. 2011 Aug 
19;333(6045):1030-4. PubMed PMID: 21852502. PMCID: PMC3164589. Epub 
2011/08/20. eng. 
238. Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-
based anti-tumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. 
Cancer Res. 2014 Jun 15;74(12):3205-17. PubMed PMID: 24736544. PMCID: 
PMC4063281. Epub 2014/04/17. eng. 
239. Hunt JS, Wood GW. Interferon-gamma induces class I HLA and beta 2-
microglobulin expression by human amnion cells. J Immunol. 1986 Jan;136(2):364-7. 
PubMed PMID: 3079784. Epub 1986/01/01. eng. 
240. Murphy GP, Hrushesky WJ. A murine renal cell carcinoma. J Natl Cancer Inst. 
1973 Apr;50(4):1013-25. PubMed PMID: 4703766. Epub 1973/04/01. eng. 
241. Perry CJ, Munoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, 
et al. Myeloid-targeted immunotherapies act in synergy to induce inflammation and anti-
tumor immunity. J Exp Med. 2018 Mar 5;215(3):877-93. PubMed PMID: 29436395. 
PMCID: PMC5839759. Epub 2018/02/14. eng. 
	 116	
242. Wiehagen KR, Girgis NM, Yamada DH, Smith AA, Chan SR, Grewal IS, et al. 
Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated 
Macrophages and Drives Potent Anti-tumor Immunity. Cancer Immunol Res. 2017 
Dec;5(12):1109-21. PubMed PMID: 29097420. Epub 2017/11/04. eng. 
243. Peng X, Kasran A, Warmerdam PA, de Boer M, Ceuppens JL. Accessory 
signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy 
with interleukin-12 for interferon-gamma production. Eur J Immunol. 1996 
Jul;26(7):1621-7. PubMed PMID: 8766570. Epub 1996/07/01. eng. 
244. Jin JO, Han X, Yu Q. Interleukin-6 induces the generation of IL-10-producing Tr1 
cells and suppresses autoimmune tissue inflammation. J Autoimmun. 2013 Feb;40:28-
44. PubMed PMID: 22921334. PMCID: PMC3524403. Epub 2012/08/28. eng. 
245. Hornebeck W, Lambert E, Petitfrere E, Bernard P. Beneficial and detrimental 
influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. 
Biochimie. 2005 Mar-Apr;87(3-4):377-83. PubMed PMID: 15781325. Epub 2005/03/23. 
eng. 
246. Pesta M, Holubec L, Jr., Topolcan O, Cerna M, Rupert K, Holubec LS, et al. 
Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and 
tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal 
carcinoma tissue samples. Anticancer Res. 2005 Sep-Oct;25(5):3387-91. PubMed 
PMID: 16101153. Epub 2005/08/17. eng. 
247. de Mingo M, Moran A, Sanchez-Pernaute A, Iniesta P, Diez-Valladares L, Perez-
Aguirre E, et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric 
carcinoma. Hepatogastroenterology. 2007 Jan-Feb;54(73):315-9. PubMed PMID: 
17419282. Epub 2007/04/11. eng. 
248. Moran A, Iniesta P, Garcia-Aranda C, De Juan C, Diaz-Lopez A, Sanchez-
Pernaute A, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal 
	 117	
cancer. Oncol Rep. 2005 Jan;13(1):115-20. PubMed PMID: 15583811. Epub 
2004/12/08. eng. 
249. Guedez L, Mansoor A, Birkedal-Hansen B, Lim MS, Fukushima P, Venzon D, et 
al. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell 
differentiation and lymphomagenesis. Blood. 2001 Mar 15;97(6):1796-802. PubMed 
PMID: 11238122. Epub 2001/03/10. eng. 
250. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncol 
Lett. 2011 Jul;2(4):583-9. PubMed PMID: 22848232. PMCID: PMC3406435. Epub 
2012/08/01. eng. 
251. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular 
signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007 
Oct;27(4):670-84. PubMed PMID: 17950003. Epub 2007/10/24. eng. 
252. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. 
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. 
Nature. 2014 Nov 27;515(7528):577-81. PubMed PMID: 25428507. PMCID: 
PMC4279952. Epub 2014/11/28. eng. 
253. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the 
patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 
2014 May;124(5):2246-59. PubMed PMID: 24667641. PMCID: PMC4001555. Epub 
2014/03/29. eng. 
254. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. 
Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J 
Clin Invest. 2011 Jun;121(6):2350-60. PubMed PMID: 21555851. PMCID: PMC3104769. 
Epub 2011/05/11. eng. 
255. Beronja S, Livshits G, Williams S, Fuchs E. Rapid functional dissection of genetic 
networks via tissue-specific transduction and RNAi in mouse embryos. Nat Med. 2010 
	 118	
Jul;16(7):821-7. PubMed PMID: 20526348. PMCID: PMC2911018. Epub 2010/06/08. 
eng. 
256. Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms 
of T cell dysfunction. Trends Immunol. 2014 Feb;35(2):51-60. PubMed PMID: 24210163. 
PMCID: PMC3946600. Epub 2013/11/12. eng. 
257. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. 
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic 
viral infection. Nat Immunol. 2009 Jan;10(1):29-37. PubMed PMID: 19043418. PMCID: 
PMC2605166. Epub 2008/12/02. eng. 
258. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic 
rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-
infected macaques. J Exp Med. 1999 Mar 15;189(6):991-8. PubMed PMID: 10075982. 
PMCID: PMC2193038. Epub 1999/03/17. eng. 
259. Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, et al. 
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program 
Initiated Early during Tumorigenesis. Immunity. 2016 Aug 16;45(2):389-401. PubMed 
PMID: 27521269. PMCID: PMC5119632. Epub 2016/08/16. eng. 
260. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T 
cell receptor antagonist peptides induce positive selection. Cell. 1994 Jan 14;76(1):17-
27. PubMed PMID: 8287475. Epub 1994/01/14. eng. 
 
